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Abstract 
Satellite cells are a distinct lineage of myogenic precursors that are responsible 
for the growth of muscle during post-natal life and for its repair after damage. 
During muscle growth and regeneration satellite cells are activated in response 
to growth signals from the environment, which induces the expression of one or 
both of the two MRFs, Myf-5 or MyoD. Activated satellite cells migrate to the 
site of injury and proliferate before these transcription factors go on to activate 
transcription of myogenic genes. The myoblasts can then adopt one of two fates. 
Some myoblasts initiate terminal differentiation and are able to either fuse into 
existing myofibres to repair them, or fuse with other myoblasts to form new 
fibres. Other myoblasts do not differentiate but instead return to quiescence and 
adopt a satellite cell position on repaired or newly formed fibres. 
 
Mighty, a downstream target of myostatin that was discovered by the Functional 
Muscle Genomics Laboratory has recently been shown to induce cell 
hypertrophy in cell culture through enhanced differentiation and fusion of 
myoblasts. Myostatin-null mice have hypertrophic muscles and an improved 
muscle regeneration phenotype. These mice have also been shown to have 
higher basal levels of Mighty in skeletal muscle than wild-type mice. In this 
thesis the expression profile of Mighty during skeletal muscle regeneration was 
characterised in relation to MyoD.  
 
During regeneration Mighty gene expression was induced at day five post-injury 
in both wild-type and myostatin-null mice. In the myostatin-null mice Mighty 
gene expression remained elevated at day seven post injury in contrast to the 
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levels in the wild-type, which had decreased at this time point. By day-14 and 
day-28 post-injury Mighty levels were decreased. The up-regulation of Mighty 
occurs at the time of peak myotube formation in regenerating skeletal muscle, 
consistent with a role for Mighty in enhancing differentiation and fusion of 
myoblasts. The extended up-regulation of Mighty in the myostatin-null muscle 
may be responsible for the enhanced regeneration phenotype of these mice. 
 
Analysis of the myotube and reserve cell populations, which are an in vitro 
model of satellite cells, from both C2C12 cells and Mighty over-expressing 
clones (Clone 7 and Clone 11) showed that Mighty expression down-regulates 
two satellite cell markers, CD34 and Sca-1. Both these molecules have been 
recently shown to be involved in myoblast fusion and reserve cell specification, 
although their exact role in these processes is not yet known. Expression of    
Sca-1 is associated with a slowly proliferating non-dividing state while CD34 is 
associated with the population of reserve cells that do not fuse when notch 
signalling is inhibited. The results of this thesis indicate that Mighty over-
expression may cause the enhanced fusion phenotype by regulating these two 
molecules. 
 
In conclusion the data in this thesis supports a role for Mighty in the myotube 
formation phase of regeneration and may be able to enhance regeneration by 
recruiting more myoblasts to terminal differentiation by altering CD34 and    
Sca-1 expression. 
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Chapter One 
Literature Review 

In this literature review, skeletal muscle structure and function will be discussed 
briefly, followed by a short review of the myogenic processes occurring during 
embryonic myogenensis. This will be followed by a review of the satellite cell, 
and its role in regeneration of skeletal muscle following injury. Finally the 
current knowledge about Mighty will be put forward. 

1.1 Muscle structure and formation 
 
1.1.1 Skeletal muscle physiology 
Skeletal muscle consists of three sheaths of connective tissue surrounding 
muscle cells, nerves and blood vessels. The epimysium surrounds the entire 
muscle, the perimysium divides the muscle up into bundles of muscle fibres 
called fascicles and the endomysium surrounds individual multinucleate muscle 
cells/fibres. Each muscle fibre is a single, multinucleate cell with a well defined 
internal structure. The internal structure of the myofibre is organised into 
bundles of myofilaments, which contain the proteins responsible for the 
contractile properties of the muscle organised into repeating units. These 
repeating units are called sarcomeres (Figure 1.1). Each sarcomere contains 
filaments of both thick and thin protein fibres. The major protein of the thick 
filaments is myosin, which is wrapped around a core of the protein titin. The 
major protein of the thin filament is actin, which is also associated with 
tropomyosin, troponin c and nebulin. The arrangement of these proteins within 
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the resting sarcomere allows three distinct regions to be described. The H zone 
is the central section of the sarcomere where only myosin filaments are present. 
The I band is the end zone where only actin filaments are present, and the A 
band is that area where the actin and myosin filaments overlap. The boundary of 
the sarcomere is defined by the Z lines, the part of the sarcomere where the thin 
filaments attach to connectins. The myosin filaments connect together at the M 
line, in the middle of the H zone. Contraction of the muscle involves action 
potentials from innervating neurons causing calcium release. Calcium floods 
into the myofibrils from the sarcoplasmic reticulum in response to the signal, 
and by binding to troponin C shifts the regulatory tropomyosin molecules away 
from the active site of the actin. The movement of the tropomyosin molecules 
allows the actin and myosin to interact, pulling the two Z lines at either end of 
the sarcomere towards each other, shortening the sarcomere length. Although 
each sarcomere only shortens a small amount, the combination of thousands of 
sarcomere shortenings results in a visible contraction of the muscle overall. 
Muscle contains three basic types of myofibres; fast, slow and intermediate 
fibres. Fast fibres, also known as Type II-B fibres can contract rapidly, and rely 
mainly on glycolysis for energy production. These fibres fatigue rapidly. Slow 
fibres, also known as Type I fibres, take three times as long to contract as fast 
fibres; however they can keep contracting for extended periods of time. As such 
muscle composed of slow fibres has more mitochondria and capillaries than 
muscle composed of fast fibres. Slow fibres also contain stores of oxygen bound 
to myoglobin, and can aerobically produce energy and thus contractions for long 
periods of time. The third kind of myofibres are intermediate fibres, also called 
Type II-A fibres. Intermediate fibres have characteristics in-between those of 
fast and slow fibres (Martini, 1998). 
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Figure 1.1: Skeletal muscle structure.  
Muscle consists of bundles of cells called fascicles. Each multinucleate cell 
contains bundles of myofibrils which are composed of repeating units of 
sarcomeres. Each sarcomere is composed of highly ordered thick and thin 
filaments. Modified from Randall et al., 1997. 
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1.1.2 Myogenesis 
1.1.2.1 Formation of somites and myogenic precursors 
During embryogenesis the somites form from the paraxial mesoderm as balls of 
epithelial cells. Somites are paired on either side of the neural tube and 
notochord and form in a rostral-caudal direction. As embryogenesis continues 
the somites differentiate dorsally to form dermomyotome and ventrally to form 
sclerotome. The dermomyotome is divisible into two segments, the epaxial 
domain which gives rise to the muscles of the back, and the hypaxial domain 
which form the muscles of the body walls and limbs (Brand-Saberi and Christ, 
1999). Signals from the tissues surrounding the somite influence the formation 
of the dermomyotome. The neural tube, notochord and surface ectoderm all 
secrete factors that influence this process (Cossu et al., 1996). Bone 
morphogenetic protein 4 (BMP-4) secreted from the dorsal neural tube up-
regulates the expression of Wnt-1 and Wnt-3a in the neural tube. These Wnt’s 
go on to activate expression of Wnt-11 in the medial lip of the dermomyotome, 
ultimately causing precursor cells to move to the myotome compartment of 
mature somites. Noggin, which inhibits BMP-4 signalling, is produced by the 
somite and prevents BMP-4 mediated inhibition of myotome formation. Sonic 
hedgehog (Shh) produced by the notochord inhibits Wnt-11 near the site of 
production, keeping Wnt-11 actions localised to the dorso-medial lip (Marcelle 
et al., 1997; Reshef et al., 1998). 

1.1.2.2 Migration to the limb bud 
The cells of the dermomyotome have been shown to be the precursors of the 
limb muscle. Cells from the somites migrate from the dermomyotome to the 
limb buds in a complicated and highly regulated process. Several factors must 
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be expressed correctly for migration to occur. Pax3, a paired domain 
transcription factor, has been shown to be essential for muscle precursor 
migration to the limb buds, as well as for the maintenance of the hypaxial 
dermomyotome (Relaix et al., 2004). In migratory cells Pax3 activates the 
expression of c-met (Epstein et al., 1996) which along with its ligand, scatter 
factor/HGF, is essential for precursor migration. In mice where either the c-met 
receptor or its ligand is knocked out, the development of the dermomyotome 
happens normally and migratory cells are formed but fail to delaminate and 
migrate away from the somites, resulting in loss of muscle masses formed by 
these cells (Dietrich et al, 1999). Lbx1 is a homeobox factor that has also been 
shown to influence migration of muscle precursors. In knock-out mice, cells 
delaminate and are able to migrate to form ventral muscle masses such as the 
diaphragm and tongue, but fail to respond to migration cues from the limb bud 
(Gross et al, 2000).  Migration of muscle precursors also involves factors that 
are involved with cell adhesion and cytoskeletal organisation such as calpain 
(Dedieu et al, 2004) fibronectin (Brand-Saberi et al., 1993) and N-cadherin 
(Brand-Saberi et al., 1996). Cells that migrate to the limb bud are maintained in 
an undifferentiated state. Activation of Notch by Delta1 has been shown to 
inhibit differentiation in the chick limb, and may also act in this capacity during 
the migration phase (Delfini et al., 2000). BMP-4 has been shown to inhibit 
myogenesis during dermomyotome formation (Marcelle et al., 1997; Reshef et 
al., 1998) and is another candidate for inhibition of myogenesis during 
migration. 
 
 

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1.1.2.3 Muscle formation in the limb bud 
After migration to the limb bud, cells undergo a period of proliferation to 
increase cell numbers. Proliferation is associated with cells that are both Myf-5 
and Pax3 positive in the chick limb bud (Delfini et al., 2000). Several factors 
have been implicated in this proliferative stage, including msx1, which is a 
homeobox factor (Houzelstein et al., 1999), hepatocyte growth factor (Yamane 
et al., 2004) and fibroblast growth factor (Itoh et al., 1996). The formation of 
skeletal muscle requires the induction of the myogenic regulatory factors 
(MRFs), which are members of the basic helix-loop-helix transcription factor 
family. They are induced and specify cells to the muscle lineage. Members of 
this family have a conserved DNA binding domain that recognises Ephrussi-
boxes (E-boxes) within the promoters of most myogenic genes. They also 
contain a heterodimerisation site that allows them to form dimers with other 
members of the E-protein family and bind to the consensus DNA binding site of 
CANNTG (Weintraub et al., 1991; Olson and Klein, 1994; Rudnicki and 
Jaenisch 1995). The first of these family members to appear in the mouse 
embryo limb bud is Myf-5, followed by myogenin and MyoD, then MRF4 
(Hannon et al., 1992). MyoD and Myf-5 appear to be involved in the 
specification of myoblast precursors and have partially overlapping roles in 
myogenesis. Lack of either factor does not result in a loss of skeletal muscle 
although Myf-5-null mice die from rib defects (Braun et al., 1992; Rudnicki et 
al., 1992). Double MyoD/Myf-5 knock-out mice completely lack myoblasts and 
differentiated muscle fibres (Kablar et al., 2003), indicating that either factor is 
sufficient to specify cells to the myogenic lineage. Myogenin is required for 
terminal differentiation of myoblast cells. Mice that lack this factor form very 
little skeletal muscle yet still have myogenic cells in the limb buds (Nabeshima 
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et al., 1993). The expression of MRF4 has an early peak in the embryo before it 
tapers off, only to be expressed again after myogenin (Lin-Jones and Hauschka, 
1996). MRF4 expression in skeletal muscle continues to remain high from this 
point and is expressed throughout adult life (Hinterberger et al., 1991). MRF4 
plays a role similar to myogenin during myogenesis. In myogenin-null mice 
muscle fibre formation can be restored by constitutively expressed MRF4 
(Sumariwalla and Klein, 2001).  More recently, two MRFs have been shown to 
interact with chromatin remodelling enzymes in the process of initiating 
myogenic gene transcription. Myogenin acts by cooperating with Mef2D and 
Brg1 chromatin remodelling enzymes to alter the chromatin around the 
promoters of myogenic genes, making transcription of these genes more likely 
(Ohkawa et al., 2006). MyoD also targets Brg1 chromatin remodelling enzymes 
to the promoters of approximately one third of MyoD induced genes. It has been 
theorised that MyoD activates myogenin by binding to Pbx sites in conjunction 
with Pbx1/Meis proteins. After chromatin structure is altered, MyoD is then 
capable of binding to the E-box sites of the promoter and inducing transcription 
(de la Serna et al., 2005). 
 
Once commitment to the myogenic lineage and terminal differentiation occurs, 
myoblasts fuse together in two waves to form primary and secondary fibres. 
Primary myotubes begin to form in the mouse extensor digitorum longus (EDL) 
by embryonic day-12 (E-12) (Ontell and Kozeka, 1984a), in the mouse soleus 
by E-14 (Ontell et al., 1988) and in the rat lumbrical muscle by E-15 (Ross et 
al., 1987). There is a lag time of two days after the formation of the primary 
myofibres before the formation of secondary fibres occurs. Secondary fibres 
initially form in close association with primary fibres and as they mature they 
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disassociate from the primary fibre. A single primary fibre may have secondary 
fibres of varying maturity associated with it (Ontell and Kozeka, 1984a; Ontell 
and Kozeka, 1984b; Ross et al., 1987; Ontell et al., 1988). 
 
 The association of myoblasts and their fusion to form myotubes requires several 
cell adhesion molecules. Neural cell adhesion molecule (NCAM) is up-regulated 
as myotubes begin to form and incubation of myoblasts with antibodies against 
this molecule prevents aggregation of fusion competent myoblasts. Both N-
cadherin and M-cadherin are expressed in myoblasts and are up-regulated at the 
beginning of myoblast fusion. Other cell adhesion molecules, such as ADAM-
12 (a disintegrin and metalloproteinase) and the integrin VLA-4 are expressed 
on myoblasts at the time of myotube formation (Abmayr et al., 2003). Although 
animals that have had NCAM and N-cadherin knocked-out have been generated, 
these animals are normal and fertile, indicating that other molecules involved in 
the fusion process are capable of compensating for their loss (Abmayr et al., 
2003). More recently other molecules involved in the fusion process have been 
identified. Myoferlin and dysferlin are required for myoblast fusion. In the case 
of myoferlin-null animals, myotube formation is impaired, although muscle still 
forms, indicating that other members of this family, or other adhesion molecules 
compensate for its loss (Doherty et al., 2005). Melanoma cell adhesion molecule 
(M-CAM) has also been shown to be involved in the fusion process. However, it 
is the down-regulation of this molecule that allows fusion to occur, not the up-
regulation as seen with other molecules (Cerletti et al., 2006).  
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1.2: The Satellite Cell 
Post-natal Muscle growth and regeneration 
 
1.2.1 Satellite cell physiology 
The satellite cell is a myogenic precursor cell that is responsible for the growth 
and repair of skeletal muscle during post-natal life. Satellite cells were first 
identified by Katz (1961) in frog muscle and have since been shown to exist in 
all vertebrate muscle. Quiescent satellite cells are mono-nuclear and are located 
at the outside edge of mature myofibres, between the fibre and the basal lamina 
(Figure 1.2). Other distinguishing anatomical features that identify the satellite 
cell are a high nuclear-to-cytoplasmic ratio, an increase in nuclear 
heterochromatin and a smaller nuclear size compared to myonuclei. As satellite 
cells activate they appear as swellings on the myofibre with cytoplasmic 
processes extending from the poles. They undergo an increase in the nuclear-to-
cytoplasm ratio and have more intracellular organelles (Schultz and 
McCormick, 1994). Satellite cells that are associated with muscle fibres appear 
at embryonic day-19 in the mouse (Cardasis and Cooper, 1975). The dorsal 
dermomyotome, which during embryogenesis provides the precursor cells for 
the limb musculature, also provides the cells that populate the satellite cell niche 
(Gros et al., 2005). 
 
Satellite cells can not be identified using phase contrast light microscopy. 
Immunocytochemistry allows for identification of these cells by the expression 
of several gene products. Two recently characterised markers for satellite cells 
are Sca-1 and CD34. Stem cell antigen-1 (Sca-1, also known as Ly-6A) was first 
identified in the haematopoietic system as an antigen that allowed for 
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purification of stem cells from bone marrow (Spangrude et al., 1988). Sca-1 
expression is also found within the spleen, thymus, kidney and within the 
vasculature of the brain, heart and liver (van de Rijn et al., 1989). More recently 
Sca-1 has been identified on cells from mouse carcinomas, sarcomas and 
melanomas (Lollini et al., 1992), on murine oesteoblasts (Horowitz et al., 1994) 
and liver sinusoidal endothelial cells (Luna et al., 2004). The gene family to 
which Sca-1 belongs (the Ly-6 family) is located on chromosome 15 (LeClair et 
al., 1987). Sca-1 is a membrane protein attached to the membrane via a 
glycosylphospha-idilinositol moiety. This attachment has been shown to be 
essential for Sca-1 to activate T-cells (Su et al., 1991).  
 
Sca-1 has also been identified in muscle. Jankowski et al. (2001) showed that 
Sca-1 is expressed on the surface of some muscle derived stem cells. Shen et al. 
(2003) identified Sca-1 as being up-regulated 19.5-fold at the beginning of 
C2C12 differentiation. Sca-1 was expressed by a sub-population of differentiating 
C2C12 cells at the time of cell cycle withdrawal. Blocking Sca-1 expression with 
antibodies resulted in cells that remained proliferative and did not form 
myotubes (Epting et al., 2004). Mitchell et al. (2005) also described two 
myoblast populations, one that was Sca-1 negative and proliferated rapidly and 
underwent differentiation, and one that was Sca-1 positive and proliferated 
slowly and did not readily differentiate. They hypothesised that Sca-1 allows a 
subset of cells to remain in an undifferentiated state much like that of the reserve 
cell population described by Yoshida et al. (1998). 
 
CD34 is a cell surface glycophosphoprotein member of the sialomucin family of 
surface molecules. It was discovered during the development of antibodies that 
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recognise subsets of marrow cells but not mature blood or lymphoid cells. CD34 
exists as a splice variant. The full length form is made from exons one through 
eight of the gene, and has a 73 amino acid intracellular domain. The truncated 
form is made when exon X is inserted between exons seven and eight, 
introducing a premature stop codon. The resulting truncated protein has only a 
16 amino acid intracellular domain. Characterisation of the function of CD34 is 
not complete, but several roles have been theorised based on the homology 
CD34 has with other proteins. CD34 is thought to be involved in cell-cell 
adhesions and in haematopoietic cell differentiation. CD34 is expressed by early 
lymphohematopoietic stem and progenitor cells, small vessel endothelial cells 
and embryonic fibroblasts (Krause et al., 1996). 
 
More recently, CD34-positive cells have been found within adult tissues not of 
haematopoietic origin. CD34 positive cells have been identified as fibroblasts 
within human breast tissue (Yamazaki and Eyden, 1995) and as fibroblasts 
associated with the interstitial cells of Cajal in the human intestine 
(Vanderwinden et al., 1999). CD34 is used as a marker of muscle-derived stem 
cells. These cells are capable of participating in skeletal muscle repair, as shown 
by the expression of dystrophin in dystrophin-deficient (mdx) mice (Lee et al., 
2000; Torrente et al., 2001). CD34-positive cells, isolated from mouse muscle 
by adherence characteristics, have a decreased fusion index compared to CD34-
negative cells yet are capable of restoring dystrophin expression in mdx muscle 
to a greater degree (Jankowski et al., 2002). CD34 has also been used as a 
marker of quiescent satellite cells. Beauchamp et al. (2000) showed that CD34 
was expressed by quiescent satellite cells. These cells also expressed Myf-5, 
indicating that they were committed to the myogenic lineage, and m-cadherin, a 
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known satellite cell marker. Thus CD34 is both a marker of satellite cells and of 
a population of muscle-derived stem cells. 
 
Other markers of satellite cells have been identified by several different groups. 
Cornelison and Wold (1997) showed that c-met receptor tyrosine kinase was 
expressed by both the quiescent and activated cells seen in fibre culture and in 
mononucleated muscle-derived cells. Syndecan 3 and 4 from the syndecan 
family of heparan sulphate proteoglycans are also expressed specifically in 
satellite cells (Cornelison et al., 2001). Satellite cells can be marked by the 
levels of lipid components in their plasma membranes. Nagata et al. (2006) 
showed that quiescent satellite cells bound lysenin to their plasma membrane, 
while activated satellite cells and myotubes did not. Garry et al. (1997) 
demonstrated that myocyte nuclear factor (MNF) was expressed persistently 
only in quiescent satellite cells and that as cells are activated, the expression 
declines. Sox8 has persistent expression in satellite cells and proliferating 
muscle precursor cells, before down-regulation during differentiation (Schmidt 
et al., 2003). Caveolin-1 has recently been identified on quiescent satellite cells, 
and its expression is down-regulated as they are activated (Volonte et al., 2005). 
M-cadherin, a member of the calcium dependent cell adhesion molecule family, 
has also been identified as a marker of satellite cells. Beauchamp et al. (2000) 
showed that 80% of quiescent satellite cells express M-cadherin, while Wernig 
et al. (2004) have demonstrated that up to 94% of cells occupying the satellite 
cell niche were positive for M-cadherin. Myf-5 has also been shown to be 
expressed by at least 80% of quiescent satellite cells (Beauchamp et al., 2000). 
In situ hybridisations have revealed that Pax7 localises to satellite cells and 
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Western blot analysis indicates that this protein is also expressed in proliferating 
muscle precursor cells (Seale et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Satellite cell position on myofibres 
Satellite cells reside between the basal lamina and the myofibre membrane 
(sarcolemma). Hawke and Garry, 2001. 

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1.2.2 Satellite cell function 
Satellite cells are a distinct lineage of myogenic precursors that are responsible 
for the growth of muscle during post-natal life and for its repair after damage. 
During muscle growth and regeneration satellite cells are activated in response 
to growth signals from the environment, which induce the expression of one or 
both of the two MRFs, Myf-5 or MyoD. Proliferating satellite cells will all 
express MyoD and some maintain Myf-5 expression (Cooper et al., 1999). 
These transcription factors go on to activate transcription of myogenic genes. 
Activated satellite cells can migrate from different areas of muscle to proliferate 
and participate in repair. The myoblasts can then adopt one of two fates. Some 
myoblasts initiate terminal differentiation and are able to either fuse into 
existing myofibres to repair them, or fuse with other myoblasts to form new 
fibres. Other myoblasts do not differentiate but instead return to quiescence and 
adopt a satellite cell position on repaired or newly formed fibres (Hawke and 
Garry 2001). Figure 1.3 illustrates this process. The mechanisms controlling 
satellite cell activation, proliferation, differentiation and self-renewal are 
discussed in the following sections. 
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Figure 1.3: Satellite cell function 
In response to activating signals, such as myotrauma, satellite cells activate, 
proliferate and differentiate to repair muscle. Hawke and Garry, 2001. 
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1.2.3 Regulation of satellite cell activation, proliferation and differentiation 
For satellite cells to play a role in the post-natal growth and repair of muscle 
they must be activated, migrate to the site of growth or injury, and proliferate 
before entering terminal differentiation. Various growth factors play roles in 
these processes, both as positive and negative regulators. Injured fibres produce 
many of the factors involved. 
 
Hepatocyte growth factor (HGF), the ligand for the c-met receptor, is expressed 
during muscle injury. The expression of HGF is proportional to the extent of 
muscle damage and exogenous injection of HGF into undamaged muscle of rats 
activates satellite cells (Tatsumi et al., 1998). Addition of exogenous HGF to 
regenerating muscle increases the number of satellite cells present, but 
depending on the time of injection can delay the regeneration process by 
inhibition of differentiation (Miller et al., 2000). HGF-mediated increases in 
satellite cell proliferation are dose dependent (Gal-Levi et al., 1998). Caveolin-1 
has recently been identified as a marker of quiescent satellite cells and is a 
downstream target of HGF signalling. HGF signalling down-regulates caveolin-
1 as a part of normal satellite cell activation (Volonte et al., 2005). 
 
Insulin-like growth factors (IGF) I and II both play a role in the activation of 
satellite cells. IGF-I is involved in activation of satellite cell proliferation via the 
IGF-I receptor (Yang and Goldspink, 2002). IGF-I stimulates proliferation and 
differentiation of myoblasts and can activate satellite cells, causing hypertrophy 
(Florini et al., 1996; Gal-Levi et al., 1998). More recently the IGF-I transcript 
has been shown to be alternately spliced into two different isoforms. One form, 
called mechano-growth factor, peaks one day after mechanical injury to muscle 
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and activates satellite cells and enhances their proliferation. IGF-IEa, the 
canonical form of IGF-I, peaks seven days after injury and enhances both 
proliferation and differentiation of the activated satellite cells (Yang and 
Goldspink 2002; Hill and Goldspink, 2003). IGF-II has been shown to stimulate 
myoblast differentiation at low concentrations and inhibit differentiation at high 
concentrations (Florini et al., 1996). IGF-II also influences regeneration of 
skeletal muscle after injury. The first stages of regeneration after injury are 
delayed by IGF-II treatment. However, late regeneration, when fibre 
enlargement occurs, is enhanced by IGF-II treatment (Kirk et al., 2003). 
 
Fibroblast growth factor (FGF) isoforms 1, 2, 4, 6, and 9 all act to stimulate 
myoblast proliferation (Sheehan and Allen, 1999), while reducing satellite cell 
differentiation (Spizz et al., 1986). FGF-2, like HGF, is released during muscle 
injury in proportion to the extent of injury (Clarke et al., 1993). When FGF-2 is 
neutralised with antibodies, the number of regenerating fibres in damaged 
muscle is decreased (Lefaucher and Sebille, 1995).  
 
Nitric oxide (NO) may be a mediator of satellite cell activation. Inhibition of 
nitric oxide synthase (NOS) is capable of inhibiting injury induced satellite cell 
activation. NOS activity is reduced in dystrophic muscle (Anderson, 2000) and 
addition of an NO donor to dystrophic muscle that has been damaged with 
bupivacaine significantly improves the regeneration of the muscle (Marques et 
al., 2005). 
 
Vascular endothelial growth factor (VEGF) receptors Flk-1 and Flk-2 are 
predominantly expressed on quiescent satellite cells of normal muscle. After 
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induction of muscle injury via ischemia they are present on activated satellite 
cells as well as newly formed myofibres, but very rarely on mature fibres. 
VEGF is a chemo-attractant for myoblasts and increases the differentiation of 
C2C12 cells in culture. VEGF is capable of reducing the number of apoptotic 
cells during differentiation, indicating that it acts as a survival factor for 
myoblasts (Germani et al., 2003). 
 
Leukaemia inhibitory factor (LIF) is a cytokine that belongs to the interleukin 6 
family. It is capable of inhibiting myoblast differentiation in vitro (Jo et al., 
2005) and administration to undamaged muscle is capable of increasing muscle 
fibre size (Gregorevic et al., 2002). LIF appears to act as a myoblast survival 
factor (White et al., 2001a). Addition of LIF to dystrophic mice that have 
received donor myoblasts results in an increase in donor derived dystrophin 
expression and improves the regeneration of the muscle (White et al., 2001b). 
LIF has also been shown to enhance regeneration in normal mice. Barnard et al. 
(1994) showed that administration of LIF to the site of a crush injury resulted in 
an increased regeneration rate and hypertrophy.  
 
Notch signalling plays a role in the regulation of satellite cell activation, 
proliferation and differentiation during muscle growth and repair. The repair of 
aged muscle can be restored to the levels seen in young mice by forced 
activation of the Notch receptor by antibodies against it (Conboy et al., 2003). 
Notch signalling inhibits MyoD expression and results in a population of cells 
that proliferate (Kopan et al., 1994). Inhibition of Notch signalling, by 
antagonists such as Numb, allows the myogenic program to be activated and 
commitment of the muscle precursors to occur (Nofziger et al., 1999; Conboy 
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and Rando, 2002). Inhibition of Notch signalling influences the self-renewal of 
satellite cells, and is capable of inducing myotube hypertrophy in cell culture by 
recruiting a sub-population of reserve cells into committed myogenensis 
(Kitzmann et al., 2006). 
 
Macrophages play an important role in muscle regeneration after injury. After 
injury muscle releases chemo-attractant cytokines and growth factors for 
macrophage and polymorphonuclear leukocyte migration and proliferation 
(Robertson et al., 1993). One such chemo-attractant is TNF-, which has been 
shown by Chen et al. (2005) to be required for muscle regeneration. Although in 
some circumstances expression of TNF- can cause cachexia (Tracey et al., 
1990), the expression of TNF- in muscle increases due to myofibre injury 
(Zador et al., 2001). Blockade of TNF- signalling by a double knock-out of the 
TNF- receptors resulted in regeneration defects due to a lack of p38-mediated 
signalling events.  
 
Both neutrophils (Kuipers et al., 1983) and macrophages expressing the ED1+ 
and ED2+ antigens are involved with phagocytosis of damaged myofibres and 
cellular debris (Honda et al., 1990; Massimino et al., 1997). Macrophages 
secrete several factors, including LIF and FGF, to attract satellite cells to the site 
of injury and enhance their proliferation and differentiation (Robertson et al., 
1993; Massimino et al., 1997). Depletion of the macrophage population by 
irradiation prior to muscle transplants abolishes regeneration in the host 
(Lescaudron et al., 1999). Macrophages have also been proposed to provide 
structural support for muscle precursor cells which can aid their growth and 
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prevent susceptibility to apoptosis through secretion of soluble mitogenic factors 
and cell contact-mediated survival signals (Chazaud et al, 2003). 
 
Syndecan-3 and syndecan-4, which are co-receptors for tyrosine kinases, have 
been shown to be expressed by satellite cells. Syndecan-3-null mice display a 
dystrophic phenotype, and isolated satellite cells show defects in MyoD nuclear 
localisation and thus differentiation. Syndecan-4-null mice do not display an 
overt dystrophic phenotype but their satellite cells have an impaired ability to 
activate, proliferate, fuse and differentiate, and like the syndecan-3-null cells 
they have MyoD localisation defects. Thus signalling through these receptors is 
necessary for correct satellite cell behaviour (Cornelison et al., 2004). 
 
Transforming growth factor-beta (TGF-), a member of the TGF- superfamily, 
is a regulator of myogenensis. Several groups have reported that TGF- is an 
inhibitor of myoblast differentiation in cell culture (Florini et al., 1986; 
Massague et al., 1986; Olson et al., 1986). TGF- is also capable of inhibiting 
satellite cell proliferation and satellite cell differentiation (Allen and Boxhorn, 
1987). Allen and Boxhorn (1989) showed that TGF- cannot reduce 
proliferation in the presence of mitogens such as IGF-I and FGF, although 
inhibition of differentiation was maintained. Thus the role of TGF- in post-
natal myogenesis and regeneration is to enhance satellite cell accumulation by 
inhibition of premature differentiation. Bone morphogenic protein (BMP), 
another member of the TGF- super-family, also inhibits terminal differentiation 
of myoblasts, by decreasing the activity of MyoD and myogenin (Katagiri et al., 
1997). 
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Myostatin, also known as growth/differentiation factor-8 (GDF-8), is also a 
member of the TGF- superfamily. Myostatin shares many characteristics with 
the TGF- family members. It has a hydrophobic amino acid core that acts as a 
secretion signal, conserved cysteine residues at the c-terminus, and a proteolytic 
processing site (Arnold et al., 2001; Sharma et al., 2001). The Belgian Blue and 
Peidmontese cattle breeds are characterised by heavy muscling and both have 
natural mutations in the myostatin gene (Kambadur et al., 1997; McPherron et 
al., 1997). Myostatin is synthesised as a precursor protein (52 kDa) and 
proteolytically processed to form a 26 kDa mature peptide in myoblasts. The 
mature myostatin protein is then secreted from the myoblasts (Thomas et al., 
2000). In vitro myostatin negatively regulates both proliferation and 
differentiation of myoblasts through two mechanisms. Proliferation is inhibited 
by up-regulation of p21, a cyclin-CDK inhibitor, causing some of the myoblasts 
to arrest in the G1-phase of the cell cycle (Thomas et al., 2000). Inhibition of 
differentiation in myoblasts occurs through a Smad3 dependent down-regulation 
of MyoD (Langley et al., 2002). 
  
Myostatin is a negative regulator of satellite cells at many levels. Skeletal 
muscle of myostatin-null mice contains more satellite cells per fibre than wild-
type mice. These satellite cells also have a greater propensity to activation and 
proliferation than cells isolated from wild-type mice (McCroskery et al., 2003). 
More recently McCroskery et al. (2005) have demonstrated in an ex vivo system 
that the presence of myostatin inhibits the activation of satellite cells on isolated 
muscle fibres, maintaining the quiescent state. Myostatin also prevents 
chemotaxis of satellite cells and macrophages, inhibiting their ability to 
participate in regeneration events after muscle damage. After muscle injury, 
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myostatin-null mice have twice the number of myogenic cells, identified by 
MyoD at the site of injury than wild-type mice. Healing is more complete with 
less fibrosis and scar tissue when myostatin is absent (McCroskery et al., 2005). 
 
1.2.4 Satellite cell heterogeneity 
Studies of satellite cells on isolated fibres have shown that they can be divided 
into two populations based on the time taken to complete the cell cycle. The 
majority (80%) take 32 hours to complete the cell cycle, while the remaining 
cells divide much more slowly (Schultz, 1996). Satellite cells also display 
heterogeneity with respect to fusion ability. Highly proliferative satellite cells 
predominantly fuse with existing myofibres, while slowly proliferating satellite 
cells predominantly fuse together (Rouger et al., 2004). Distinct sub-populations 
of cells can be derived from satellite cell culture. When C2C12 cells are induced 
to differentiate a proportion of the cells commit to terminal differentiation, while 
a different population withdraw from the cell cycle and do not differentiate. 
Isolation and culture of undifferentiated cells results again in the formation of 
two populations of cells, one differentiated, one undifferentiated (Yoshida et al., 
1998). Satellite cells also exhibit this heterogeneity with respect to proliferation 
(Barani et al., 2003) and fusion (Baroffio et al., 1996), indicating that the C2C12 
culture is a good in vitro model of satellite cells. In addition to the heterogeneity 
seen with respect to cell cycle time, fusion and ability to terminally differentiate, 
satellite cells differentially express satellite cell markers such as CD34 and Myf-
5, as described in Section 1.2.1. 
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1.2.5 Satellite cell self-renewal 
To maintain the capability of muscle to repair during post-natal life the pool of 
cells responsible for this repair, the satellite cells, must be maintained. Satellite 
cells are persistent in degenerative myopathies such as muscular dystrophy, 
indicating an ability to self-renew (Bischoff, 1994). Pathways involved for self-
renewal of satellite cells are complex, as the cell must either withdraw from a 
proliferative state to G0 or undergo cell cycle arrest at the G1/S transition.  
 
Evidence for self-renewal has come from cell labelling studies. When cells 
expressing a nuclear localising LacZ gene are injected into dystrophic muscle, 
nuclei that stain positive for -Gal staining are derived from donor nuclei. 
Nuclei staining positive are found not only within existing myofibres, but within 
the satellite cell niche. Isolation and culture of these cells gives rise to further 
myoblasts, indicating that they are functional satellite cells (Blaveri et al., 1999; 
Heslop et al., 2001). Evidence for a role of the MRF’s in self-renewal has come 
from studies of MyoD-null mice. MyoD-null cells have higher levels of Myf-5, 
display differentiation defects, and have an increased tendency towards self-
renewal than wild-type cells. One theory to account for this is that Myf-5 is 
involved in specification of the cells towards self-renewal (Megeney et al., 
1996; Sabourin et al., 1999). Pax7 may also be involved in satellite cell self-
renewal or muscle-stem-cell specification. Pax7-null mice appear to completely 
lack satellite cells yet they still have a population of cells called side population 
cells (SP). SP cells from normal mice, when cultured under certain conditions, 
will give rise to cells from both the haematopoietic and the myogenic lineages. 
SP cells from the Pax7-null mice have an increased tendency towards forming 
haematopoietic colonies, indicating that Pax7 is involved in satellite cell 
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specification (Asakura et al., 2002). Dedifferentiation of terminally 
differentiated cells may be another way in which the satellite cell niche is 
repopulated. Forced expression of msx1, a homeobox transcription factor, in 
C2C12 myoblast lines is capable of causing myotubes to cease expression of 
MRF’s and give rise to proliferating mononuclear cells (Odelberg et al., 2000). 
 
Asymmetrical cell division, which results in one daughter cell adopting a 
differentiation committed state and the other returning to quiescence is proposed 
to be a mechanism allowing myoblasts to self renew. Zammit et al. (2004) have 
shown that the majority of satellite cells co-express Pax7 and MyoD after 
activation. Some of these cells will down-regulate Pax7 and differentiate, while 
others maintain Pax7, down-regulate MyoD and withdraw from differentiation, 
presumably to repopulate the quiescent satellite cell niche. Notch signalling is 
also coming to be understood as a regulator of satellite cell quiescence. 
Proliferative progeny of satellite cells localise Numb, an inhibitor of Notch 
signalling, asymmetrically during division, with one daughter cell becoming 
Numb+ and one becoming Numb-. Numb+ cells go on to express markers of 
myogenic commitment, such as Myf-5 and desmin, while Numb- cells retain 
Pax3 expression and may re-enter the quiescent state (Conboy and Rando, 
2002). Self-renewal of satellite cells is negatively regulated by myostatin. 
Myostatin-null mice have a higher proportion of CD34-positive cells per unit 
fibre length than their wild-type counterparts, indicating that activated satellite 
cells have self-renewed to a greater extent than seen in wild-type mice 
(McCroskery et al., 2003). 
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1.2.6 Other sources of myogenic precursors 
Other possible sources of myogenic precursors that participate in muscle 
regeneration have been identified. Mouse neural tube (Tajbakhsh et al., 1994), 
the periventricular region of the mouse brain (Galli et al., 2000) and human 
adipose tissue (Zuk et al., 2001) all contain cells that are capable of expressing 
myogenic markers. The haematopoietic system is another possible source of 
myogenic cells. Circulating AC133+ cells isolated from blood can express the 
myogenic markers Myf-5, M-cadherin and Pax7, and will differentiate into 
muscle when co-cultured with committed myogenic cells (Torrente et al., 2004).  
Ferrari et al. (1998) reported that donor bone-marrow-derived nuclei that stained 
positive for -Gal were present within muscle fibres of regenerating TA of 
immune deficient mice, although at a lower frequency than that seen in control 
muscles injected with donor satellite cells. Recently, however, some doubt has 
been present as to the extent that bone-marrow derived cells can participate in 
functional restoration of muscle. Lapidos et al. (2004) demonstrated that bone 
marrow derived cells could fuse with existing myofibres, but their ability to 
produce muscle specific genes to alleviate a muscular dystrophy phenotype was 
impaired. 
 
A different source comes from a lineage of CD45+ cells that reside within the 
muscle. These cells, called side population (SP) cells for their ability to exclude 
Hoechst dye, are found in all muscle including that from Pax7-null mice which 
lack satellite cells. SP cells from normal mice will form haematopoietic colonies 
in cell culture when cultured alone, and differentiate into myotubes when co-
cultured with committed myogenic precursors (Asakura et al., 2002). SP cells 
are also able to undergo myogenic commitment during regeneration in response 
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to Wnt signalling (Polesskaya et al., 2003). Induced muscle damage increases 
the number of CD45+ cells present, and a large number of these can acquire 
myogenic potential (Seale et al., 2003). 
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1.3 Mighty 
 
1.3.1 Discovery and characterisation of Mighty 
Novel downstream targets of myostatin have been identified by the Functional 
Muscle Genomics (FMG) Laboratory, AgResearch, Ruakura, in order to 
elucidate the mechanisms by which myostatin is able to negatively regulate 
muscle mass. One of the target genes, identified as being up-regulated 58% in 
myostatin-null mice by suppressive subtraction hybridisation, is a cDNA that 
has been called Mighty. At the time of discovery the protein encoded by this 
cDNA had no known function. Characterisation of the Mighty gene by 
homology searches, calculations of the theoretical size and pI of the protein, 
secondary structure predictions, protein domain homology searches, prediction 
of post-translational modifications and subcellular localisation predictions have 
all been carried out. 

Mighty has been shown by Northern analysis to be up-regulated specifically in 
mouse skeletal muscle, from a 48% increase in the m. gastrocnemius (the lowest 
increase seen) to a 106% increase in the m. masseter in mice. The mouse Mighty 
cDNA shares 96% and 89% homology and the protein shares a 98% and 93% 
homology with the rat and the human respectively. Conservation of the Mighty 
sequence is seen to some extent throughout the animal kingdom, implying that 
the function of Mighty is biologically important. Mouse Mighty has been 
located to chromosome four and contains five exons and four introns. The 
predicted protein size is 22 kDa and the protein should have a pI of 8.91. There 
is a high probability that the protein is localised to the nucleus, however, any 
DNA binding domains are yet to be characterised. Several possible 
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phosphorylation sites exist within the protein, along with two possible 
myristoylation sites.  

The Mighty protein is predicted to have a secondary structure that consists of 
three -helices. Tertiary structure is difficult to predict as the sequence has little 
homology with proteins of known function. A possible forkhead domain is 
predicted for Mighty, but as it shares little homology with known proteins of 
this kind it is likely to be either a distantly related or a novel member of this 
family (Bishop, 2005). 

1.3.2 Mighty cellular localisation 
Results (unpublished) from the Functional Muscle Genomics Laboratory show 
that endogenous Mighty protein localises to speckles in the nucleus, to 
perinuclear regions and to the endoplasmic reticulum. Mighty has been shown to 
be co-localised with lamin, a protein of the nuclear lamina in the nuclear 
speckles. This localisation of Mighty with lamins, which have been shown to 
bind DNA at matrix attachment regions (MARs) (Luderus et al., 1992, 1994) of 
regulatory DNA sequences (Boulikas, 1994, 1995), may be a possible 
mechanism for Mighty to regulate gene expression. 

1.3.3 Mighty over-expression 
Over-expression of Mighty in the C2C12 cell line causes myoblast hypertrophy 
but does not affect the rate of cell proliferation as measured by methylene blue 
assay. Mighty over-expressing clones show an enhanced fusion phenotype and 
the resulting myotubes are hypertrophied. Regulatory molecules of 
differentiation, such as MyoD and Myogenin, are up-regulated earlier in the 
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Mighty over-expressers. The differentiation marker myosin heavy chain (MHC) 
is seen earlier than in control cells. Conditioned media taken from Mighty clone 
cultures has the ability to alter the phenotype of normal C2C12 cells to one like 
that of the over-expressers (Bishop, 2005). 

1.3.4 Mighty promoter regulation 
The Mighty promoter region has been shown to extend -1963 to +129 bp around 
the transcription start site. Promoter activity analysis indicates that the minimal 
promoter required extends from -158 to +129. Activity of the promoter 
decreases as more upstream elements are added, indicating that repressive as 
well as enhancer elements are found in these regions. Prediction of transcription 
factor binding sites suggest that the promoter contains TATA sequences, Sp1 
binding sites, AP-1 binding sites, E-box motifs, two of which are MyoD 
specific, GATA binding motifs, an E2F binding site, a NFB binding site, an 
E4BP binding site, an E47 binding site, MZF1 binding sites and AML-1a sites.  

As expected, myostatin treatment is able to down-regulate the Mighty promoter 
in a dose-dependent fashion. Treatment of truncated fragments of the promoter 
with myostatin indicated that very little (80 bp upstream of transcription 
initiation) is required for myostatin-regulated inhibition. Further studies have 
shown that one pathway through which myostatin down-regulates the Mighty 
promoter is by binding to the ActIIB and ALK5 receptors which causes 
formation of inhibitory Smad 2/3 complexes. Myostatin is also able to 
negatively regulate the Mighty promoter via the MEK and pI3K pathways 
(Bishop, 2005). 
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1.4: Aims and Objectives 
 
 
Satellite cells play an important role in post-natal growth and regeneration of 
muscle. Myofibre nuclei are post-mitotic and as such are unable to proliferate to 
meet an increase in muscle demand during growth and exercise-induced 
hypertrophy. Satellite cells are also activated after muscle injury, in response to 
various stimuli, to participate in the repair of damaged muscle fibres. Several 
factors regulate satellite cell activation. An important negative regulator of 
muscle satellite cells is myostatin. Lack of myostatin in myostatin-null mice 
results in larger muscles than their wild-type counterparts, with a larger pool of 
activated satellite cells that remain in the cell cycle longer before withdrawing 
for terminal differentiation. A genetic screen performed on myostatin-null and 
wild-type mouse muscle identified a novel gene ‘Mighty’ which is up-regulated 
in the knock-out muscle.  
 
Mighty is a putative transcription factor that is up-regulated between 48% and 
106% in the skeletal muscles of myostatin-null mice. Mighty is a putative 
transcription factor that has been shown to be involved in muscle hypertrophy. 
Over-expression of Mighty in C2C12 cells results in an enhanced fusion and 
hypertrophic phenotype (Bishop, 2005). Thus our hypothesis is that Mighty is a 
transcription factor involved in the activation of satellite cells for growth and 
regeneration, like MyoD and Myf-5. The aims of this thesis were to firstly 
characterise the expression of Mighty in both quiescent and activated satellite 
cells from wild-type and myostatin-null mice, secondly to characterise Mighty 
expression during muscle regeneration, and thirdly to look at the effect of 
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Mighty over-expression on the reserve cell population of C2C12 cells as an in 
vitro model of satellite cells. 
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Chapter Two 
Materials and Methods 
 
2.1 Materials 
2.1.1 Oligonucleotide primers for PCR amplification 
Oligonucleotide primers were designed for use in Polymerase Chain Reaction 
(PCR) amplifications to generate the respective gene products, and were 
obtained from Invitrogen. All oligonucleotides were re-suspended in 100 µl of 
sterile water and stored at -20oC. Primers were diluted to 10 µM with sterile 
water for use in PCR reaction. All diluted primer aliquots were stored at -20oC. 
The primers used are described in Table 1. 
 
Table 1: Oligonucleotide Primers 
Gene Primer Sequence 
(5` to 3`) 
Product 
size (bp) 
Primer 
source 
Mighty Fwd: TGAAGCGGCCCATGGAGTTC 
Rev: GGTGGGCTGGTCCTTCTTCA 
350 Designed 
in house 
CD34 Fwd: AGCACAGAACTTCCCAGCAA 
Rev: CCTCCACCATTCTCCGTGTA 
Trunc:416 
Full: 250 
Ref 12 
Sca-1 Fwd: CGAGGGAGGGAGCTGTGAGGTT 
Rev: GAGGGCAGATGGGTAAGCAAAGAT 
285 Ref 103 
MyoD Fwd: CGGCGGCAGAATGGCTACGA 
Rev: TGCAGTCGATCTCTCAAAGC 
350 Ref 98 
-
Tubulin 
Fwd: GCTTCTTGGTTTTCCACAGC 
Rev: CATGGTAGGCTTTCTCAGCA 
450 Designed 
in house 
 
2.1.2 Mammalian cell lines 
C2C12 myoblasts (Yaffe and Saxel, 1977) were used for myotube and reserve 
cell enrichments and were sourced from the American Type Culture Collection 
(ATCC). C2C12 cell lines over-expressing a Mighty gene construct were made in 
house. All cells were grown in Dulbecco’s modified eagle medium (DMEM) + 
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10% fetal bovine serum + 20% horse serum for proliferation and in DMEM + 
2% horse serum for differentiation, at 37oC/5% CO2. 

2.1.3 Animals 
Female and male wild type mice, strain C57BL/10, used in these experiments 
were bred at the Ruakura Small Animal Colony. Male and female myostatin-
null mice, originally sourced from Se-Jin Lee (Johns Hopkins University, 
Baltimore, USA), were also bred in the Ruakura Small Animal Colony. All mice 
used in the study were 4-6 weeks of age. Animals were kept at constant 
temperature (20-22oC) with a natural day/night cycle and food and water ad 
libitum. All animal manipulations were carried out according to the standard 
operating procedures approved by the Ruakura Animal Ethics Committee. 

2.1.4 Antibodies 
Antibodies used for immunocytochemisty (ICC) or Western blot in this thesis 
are described in Table 2. 
Table 2: Antibodies 
Antibody Source Use Dilution 
Mighty QED Biosciences Western 1:5000 
Mighty QED Biosciences Cell ICC 
Tissue ICC 
1:200 
1:100 
MyoD Santa Cruz Biotechnology Cell ICC 1:100 
Desmin Sigma Aldrich Cell ICC 1:200 

2.1.5 Solutions 
Common solutions used were made according to Ausubel et al. (1987), 
Sambrook et al. (1989) and/or Lillie (1965) and are listed in the Appendix. 


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2.2 Methods
 
2.2.1 Isolation of satellite cells using Percoll gradients 
Quiescent satellite cells were isolated from hind-limb muscle of mice using a 
protocol adapted from Yablonka-Reuveni and Nameroff (1987).  

Four to five week old mice were euthanised by CO2 aspyhxiation and cervical 
dislocation. The entire hind limb muscle was dissected out and weighed. 
Approximately 2 g of muscle was used per Percoll (Sigma Aldrich) column as 
described below. The muscle was thoroughly minced using a scalpel in PBS 
then transferred to a 50 ml tube and centrifuged at 600 rcf at room temperature 
for five minutes before being digested in Dulbecco’s modified eagle medium 
(DMEM) without serum and containing 0.2% collagenase Type 1A at 37oC and 
with constant shaking (70 rpm). After 90 minutes of digestion, 10 ml PBS was 
added to each digest followed by centrifugation at 1400 rcf. The supernatant, 
containing the collagenase, was removed and replaced with 10 ml PBS, and then 
the slurry was triturated for five minutes before being passed through a 70 µm 
filter. The filtered cells were centrifuged at 1400 rcf for ten minutes before re-
suspension in 3 ml PBS. During centrifugation, a 90% Percoll solution was 
made from 9 parts Percoll to 1 part 10x PBS. Percoll solutions of 40% and 70% 
were made from the 90% Percoll using sterile 1x PBS, then used to create a 
gradient by underlying 3 ml of 40% Percoll with 3 ml of 70% Percoll in a 15 ml 
tube. The cell suspension was laid on top of the gradient, and then the gradient 
was centrifuged in a Sorval RC-3B refrigerated centrifuge in a H2000B rotor at 
1450 rcf for 20 minutes at 25oC without a brake. The top layer of the gradient 
containing fibroblasts and debris was discarded, and then the satellite cells from 
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the 70%/40% interface were removed to a clean 15 ml tube. The cells were 
washed with PBS then centrifuged at 1700 rcf for ten minutes. This wash step 
was repeated two to three times. Cells were re-suspended either in protein lysis 
buffer for Western analysis or in Trizol (Invitrogen) for RNA extraction.  

2.2.2 Isolation of satellite cells by adherence to Matrigel coated plates 
Activated satellite cells (primary myoblasts) were isolated from hind limb 
muscle of mice using a protocol adapted from Allen et al. (1997) and Partridge 
(1997).  

Entire hind limb muscle was dissected out and thoroughly minced with a scalpel 
in phosphate buffered saline (PBS). The minced muscle was transferred to a 50 
ml tube and centrifuged at 600 rcf at room temperature for five minutes before 
being digested in DMEM without serum and containing 0.2% collagenase Type 
1A at 37oC and with constant shaking (70 rpm). After 90 minutes of digestion, 
the sample was centrifuged at 1400 rcf for 10 minutes. The supernatant, 
containing the collagenase, was removed and replaced with 10 ml PBS. The 
slurry was triturated for 5 minutes then passed through a 100 µm filter, then a 70 
µm filter. The volume of the sample was made up to 35 ml with sterile PBS then 
centrifuged at 600 rcf for ten minutes. After centrifugation the supernatant was 
removed and the cells were re-suspended in 8 ml satellite cell proliferation 
media. The cells were pre-plated on uncoated 10 cm Nunc cell culture Petri 
dishes for two hours at 37oC/5% CO2 to allow fibroblasts to attach. After pre-
plating, the cell suspension was plated onto Matrigel-coated Nunc plates and 
incubated at 37oC/5% CO2 for 48 hours. After 48 hours the cells were washed 
with sterile PBS then trypsinised and re-suspended in Trizol (Invitrogen) for 
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RNA extraction and cDNA synthesis or protein lysis buffer for Western 
analysis. 
 
2.2.3 Notexin injection to induce muscle regeneration 
Both wild-type and myostatin-null mice were used in this trial. Mice were 
anaesthetised by intraperitoneal injection of ketamine/rompun (ketamine 
hydrochloride 100mg/ml, xylazine hydrochloride 20 mg/ml) at 0.1 ml per 6 g 
body weight. Once anaesthetised, a small incision was made in the skin above 
the right tibialis anterior (TA) and 0.1 µg of notexin (Notechis scutatus, Venom 
Supplies Pty. Ltd., Tanunda, South Australia) was injected into the muscle. At 
time points of day 0, 1, 2, 3, 5, 7, 14 and 28, five mice were euthanised by CO2 
asphyxiation and cervical dislocation and had both the treated and control 
(contra-lateral) TA removed. The muscles from three mice were frozen in liquid 
nitrogen for RNA extraction. The muscles from the remaining two mice were 
fixed for tissue sectioning. Tissues were coated in Tissue Tek O.C.T compound 
(Sakura) then frozen in liquid nitrogen-cooled iso-pentane (BDH) for ten 
seconds. Tissues were then moved to liquid nitrogen. All tissues, for both RNA 
and tissue sectioning, were stored at -80oC until use. 
 
2.2.4 Isolation of Reserve cell populations 
Reserve cells were isolated from cultures of both normal C2C12 cells and from 
stably-transfected cell lines expressing Mighty, according to the method of 
Kitzmann et al. 1998. Cell cultures were plated on 10 cm diameter Nunc culture 
dishes at a density of 25,000 cells/cm2 and allowed to attach for 16 hours. 
Differentiation media (DMEM + 2% horse serum) was added and the cultures 
were incubated at 37oC/5% CO2 for 72 to 96 hours. Following this a short 
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trypsinisation was carried out (five minutes, 0.15 % trypsin) and the myotubes 
were removed with two PBS washes. The reserve cells, which remain attached 
during this procedure, were then removed by a ten minute incubation with 
0.25% trypsin. Isolated myotube or reserve cell populations were stored at -80oC 
in Trizol (Invitrogen). 

2.2.5 RNA isolation  
From whole tissue: 
Total RNA was isolated from tissue samples using Trizol (Invitrogen) according 
to the manufacturer’s protocol. 

TA muscles isolated from notexin-injected mice were homogenised with 1 ml 
Trizol per 50 mg of tissue. An initial spin at 12,000 rcf for ten minutes at 4oC 
was carried out to pellet cellular debris. 200 µl of chloroform per 1 ml Trizol 
was added and incubated for two to three minutes before centrifugation at 
12,000 rcf for 15 minutes at 4oC. The upper aqueous phase was removed to a 
clean Eppendorf tube and had an equal volume of chloroform added. The 
samples were centrifuged at 12,000 rcf for 15 minutes at 4oC, and then the upper 
aqueous layer was removed to a clean tube. Total RNA was precipitated by 
adding 500 µl of isopropanol per 1 ml of Trizol to the aqueous phase. Samples 
were incubated at room temperature for ten minutes then centrifuged at 12,000 
rcf for ten minutes at 4oC. The RNA pellet was washed with 1 ml 75% ethanol 
made with DEPC water, then centrifuged at 7,500 rcf for five minutes at 4oC. 
The RNA pellets were dried for five to ten minutes then re-suspended in DEPC 
water. Incubation at 55-60oC for ten minutes completed the re-suspension. RNA 
was stored at -80oC. 
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From cultured cells: 
Total RNA was isolated from cultured cells using Trizol (Invitrogen) according 
to the protocol mentioned above but with the changes outlined below. 

Media was removed from the plates and the cells were washed twice with PBS.   
1 ml Trizol was added to each plate to lyse the cells. All cells were removed 
from the plates by pipetting the Trizol over the surface several times. The Trizol 
was removed to Eppendorf tubes and had 200 µl chloroform added. From this 
point on the protocol was essentially as described above. 

All RNA was quantified using a Nanodrop ND-1000 spectrophotometer 
(NanoDrop Technologies). 1 l of a 1:10 dilution of the RNA was pipetted onto 
the detector and the absorbance at 230, 260 and 280 nm was read and used to 
determine the quantity of RNA in the sample. 

2.2.6 First Strand cDNA Synthesis 
cDNA for use as a template in the PCR was generated using SuperScript First-
Strand Synthesis System for RT-PCR (Invitrogen) following the manufacturer’s 
protocol. 

1-5 µg total RNA was added to 1 µl 10 mM dNTPs and 1 µl Oligo(dT)12-18 
primer, then made up to 10 µl with DEPC-treated water. The RNA was 
incubated at 65oC for five minutes, then on ice for at least one minute. 9 µl of a 
reaction mix containing RT buffer, MgCl2, DTT and RNaseOUT, was added to 
the RNA and incubated at 42oC for two minutes. 1 µl of Superscript II reverse 
transcriptase was added to each reaction. The reactions were incubated at 42oC 
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for 50 minutes then at 70oC for 15 minutes. 1 µl RNaseH was added to each 
tube then incubated at 37oC for 20 minutes. All cDNA was stored at -20oC. 
 
2.2.7 Polymerase Chain Reaction (PCR) 
PCR amplifications were carried out using Taq DNA Polymerase (Roche). PCR 
reactions (50 µl) contained 1 x PCR buffer, varying concentrations of template, 
both sense and antisense primers at 0.2 µM, and dNTPs at 0.2 mM. A Hybaid 
MBS 0.5S PCR System (Hybaid) was used for the thermocycling of the PCR 
reactions.  PCR amplifications for Mighty contained 1 x Q solution in addition 
to the reagents listed above. 
 
PCR amplifications were standardised on cDNA templates derived from either 
wild type mouse TA muscle or C2C12 cells differentiated for 72 hours. PCR 
primers are described in Table 1 and cycle conditions are described in Table 3. 
 
Table 3: PCR cycle conditions. 
Wt TA cDNA
 
Product Denaturation  Annealing Extension 
Mighty 94oC, 20 s 60oC, 45 s 72oC, 1 min 
MyoD 94oC, 15 s 60oC, 40 s 72oC, 1 min 
72 hr differentiated C2C12 
Mighty 94oC, 20 s 60oC, 45 s 72oC, 1 min 
Sca1 94oC, 20 s 62oC, 45 s 72oC, 45 sec 
CD34 94oC, 20 s 58oC, 45 s 72oC, 45 sec 
Tubulin 94oC, 20 s 55oC, 30 s 72oC, 1 min 
 
To determine the linear increase during the amplification PCRs were carried out 
on the templates mentioned above. Cycle numbers of 20-30 were well 
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standardised to determine the linear increase in product. The PCR products were 
then run on a 1% agarose gel and stained with ethidium bromide. 
 
2.2.8 RNA and DNA analysis 
1.2% denaturing RNA gels were made according to the protocol in the 
Appendix. 0.5 to 1 µg of total RNA was mixed with an equal volume of 2 x 
RNA loading dye and incubated at 65oC for five minutes before loading. Gel 
visualisation was carried out on a BioRad Gel Doc 2000. 

DNA gels were made according to the protocol in the Appendix. To ensure the 
gels were consistent, the volume of agarose, the volume of ethidium bromide 
per gel and the same gel running conditions were used. To visualise the products 
of the PCR reactions, 5 µl of PCR product was combined with 1 µl of 10 x DNA 
loading dye and run on the gels. Agarose gels were exposed to UV light by a 
BioRad Gel Doc 2000, with the same exposure settings used each time. Pictures 
of the gels were saved for analysis using BioRad Quantity One 4.4.1 software. 
 
2.2.9 Immunocytochemistry for Mighty on tissue sections
The tissues recovered from the regeneration trial described in Section 2.2.3 were 
sectioned using a Leica Cryocut 1800. Sections cut were 10 µm thick and stored 
unfixed on Esco POLYSINE microscope slides (Biolab Scientific) at -20oC until 
analysis. For Mighty detection, the sections were thawed in a humid chamber, 
then a circle was drawn around the edge of the tissue with a PAP pen (Zymed 
Laboratories Inc.). Sections were blocked in PBS-T + 0.2% BSA + 10% normal 
donkey serum (NDS) for 30 minutes at room temperature. Primary rabbit anti-
Mighty antibody was added at 1:100 in PBS-T + 0.2% BSA + 5% NDS 
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overnight at 4oC in a humid box. As a negative control, primary antibody was 
not added to one section. The next day the slides were washed three times in 
PBS for four minutes each wash. Sections were fixed in 10% formalin for five 
minutes at room temperature then washed three times in PBS for four minutes 
each wash. Secondary antibody was added at 1:300 in PBS-T + 0.2% BSA + 5% 
NDS for one hour at room temperature. The slides were then washed three times 
in PBS-T 0.2% for four minutes per wash.  Tertiary antibody was added at 1:400 
in PBS-T + 0.2% BSA in a dark humid box for one hour at room temperature. 
Slides were washed twice in PBS for four minutes per wash, and then had DAPI 
added at 1:1000 in PBS and were incubated for five minutes. Slides were again 
washed twice in PBS for four minutes each wash, then were dried and had cover 
slips mounted with DakoCytomation fluorescent mounting medium (Med-bio 
Ltd). Slides were stored wrapped in tinfoil and at 4oC. Slides were viewed using 
an Olympus BX50 Microscope (Olympus Optical Co., Germany) with an 
attached camera. Images were taken using Spot Basic software (Spotsoftware, 
Diagnostic Instruments Inc.). Comparisons of Mighty levels and of infiltrating 
nuclei numbers between the wild-type and myostatin-null tissues was done by 
simple visual estimation. 
 
2.2.10 Immunocytochemistry on satellite and C2C12 cells 
Immunocytochemisty (ICC) was carried out for MyoD on Percoll-isolated 
satellite cells, for Desmin on Matrigel-isolated satellite cells and for Mighty on 
reserve cells derived from C2C12 cells and Mighty over-expression clones.  
 
Satellite cells isolated by the Percoll method (Section 2.2.1) were aliquoted onto 
Lab-Tek 8-well chamber slides that had been pre-coated with poly-L-lysine 
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(Sigma, 0.01% solution). After a 30 minute incubation to allow cells to attach to 
the slide, the excess suspension was removed and the cells were fixed, blocked 
and incubated with antibodies against MyoD as described in Table 4 and Table 
5. 
 
Matrigel-isolated satellite cells (Section 2.2.2) were allowed to proliferate for 24 
hours on a 10 cm Matrigel-coated plate. The cells were then trypsinised and 
plated onto a Matrigel-coated Lab-Tek 8-well chamber slide at a cell density of 
15,000 cells/cm2 and allowed to attach and proliferate for a further 24 hours. 
Excess media was removed and the cells were fixed, blocked and incubated with 
antibodies against Desmin as described in Table 4 and Table 5. 
 
C2C12 cells and Mighty over-expressing clones were plated on Permanox slides 
(Invitrogen) and allowed to proliferate for 24 hours before being switched to 
differentiation media (DMEM + 2% HS). Cells were differentiated for 72 to 96 
hours then subjected to a limited trypsinisation, as outlined in Section 2.2.4. The 
remaining reserve cells were then fixed, blocked and incubated with antibodies 
against Mighty as described in Table 4 and Table 5. 
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Table 4: Immunocytochemisty conditions. 
ICC Slide type Fixation Permeablisation Blocking 
MyoD 8-well, 
poly-l lysine 
coated 
30 s of 20:2:1 
fixative per well 
0.5% Triton X-100 
in PBS, 10 min at 
RT 
0.35% C- 
in PBS + 
10% NDS, 1 
h RT 
Desmin 8 well, 
Matrigel 
coated 
30 s of 20:2:1 
fixative per well 
0.5% Triton X-100 
in PBS, 10 min at 
RT 
0.35% C- 
in PBS + 
10% NSS, 1 
h RT 
Mighty Permanox 30 s of 20:2:1 
fixative per well 
0.5% Triton X-100 
in PBS, 10 min at 
RT 
5% BSA in 
PBS + 5% 
NGS, 4 h 
RT 
 
Table 5: Immunocytochemistry conditions continued 
ICC Primary Secondary Tertiary 
MyoD 1:100 in 0.35% 
C- in PBS + 5% 
NDS, O/N at 4oC 
1:300 in 0.35% C- 
in PBS + 5% NDS, 1 
h at RT 
1:400 in 0.35% C- 
in PBS + 5% NDS, 1 
h at RT in dark 
Desmin 1:200 in 0.35% 
C- in PBS + 5% 
NSS, O/N at 4oC 
1:300 in 0.35% C- 
in PBS + 5% NSS, 1 
h at RT 
1:400 in 0.35% C- 
in PBS + 5% NSS, 1 
h at RT in dark. 
Mighty 1:200 in 2.5% 
BSA in PBS + 
2.5% NGS, O/N 
at 4oC 
AF488 conjugated 
secondary at 1:300 in 
2.5% BSA in PBS + 
2.5% NGS, 1 h at RT  
Not applicable 
 
In between each step the slides were washed in PBS-T (satellite cells) or TBS-T 
(C2C12) for three rounds of five minutes. After the tertiary antibody incubation, 
all slides were stained with DAPI (1mg/ml) at 1:1000 in PBS for five minutes. 
All slides had cover slips mounted with DakoCytomation fluorescent mounting 
medium (Med-bio Ltd). Slides were stored wrapped in tinfoil and at 4oC. Slides 
were viewed using an Olympus BX50 Microscope (Olympus Optical Co., 
Germany) with an attached camera. Images were taken using Spot Basic 
software (Spotsoftware, Diagnostic Instruments Inc.). 
 
To determine the percentage of myogenic cells from the Percoll and Matrigel 
isolations, random images were taken from both the positive and negative wells. 
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All nuclei per image, as stained blue by DAPI, were counted, and then the 
number of cells that stained for MyoD or Desmin (green) were counted. 
 
2.2.11 Haematoxylin and eosin staining 
Sections on slides were submerged in Gill’s haematoxylin stain for four 
minutes, then washed in tap water until the water ran clear. The slides were then 
submerged in Scott's tap water for three minutes then rinsed in tap water for          
two minutes. Slides were stained in eosin for two minutes then washed in tap 
water until the water ran clear then for a further two minutes. The sections were 
then dehydrated by 30 seconds in 50% ethanol, one minute in 70% ethanol, one 
minute in 95% ethanol, two minutes times two in 100% ethanol then five 
minutes times two in xylene. Cover slips were mounted using xylene-based 
DPX mounting for microscopy (BDH). Slides were viewed using an Olympus 
BX50 Microscope (Olympus Optical Co., Germany) with an attached camera. 
Images were taken using Spot Basic software (Spotsoftware, Diagnostic 
Instruments Inc.). 
 
2.2.12 Western Blotting 
Protein extraction from Percoll isolated satellite cells 
Total protein was extracted from satellite cells for analysis by Western Blotting. 
Harvesting of the cells was performed as described in Sections 2.2.1 and 2.2.2. The 
cell lysate was passed through a 0.45 mm gauge syringe needle ten times. The cell 
lysate was then centrifuged at 12000 rcf at room temperature for ten min. The 
supernatant was removed and the protein concentration was determined by mixing     
1 µl of protein with 99 µl PBS and 1.2 ml of a 1:5 dilution of Bio-Rad protein assay 
Dye Reagent Concentrate, then reading the absorbance at 595 nm. The 
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concentration was calculated from a standard curve of 0, 5, 10, 15 and 20 g BSA 
standard prepared from a 5 µg /µl stock of BSA solution. 
 
 
SDS polyacrylamide gel electrophoresis 
Separation of protein for Western blotting was achieved using NuPage 4-12% 
gradient Bis-Tris pre-cast polyacrylamide gels (Invitrogen) in a XCELL II Mini gel 
apparatus (Novex) with 1 x Nupage MES SDS running buffer (Invitrogen). Samples 
were mixed with 4 x NuPage Sample Buffer (Invitrogen) containing -
mercaptoethanol before boiling for five minutes. The SeeBlue Plus2 Pre-Stained 
Standard (Invitrogen) was used as a molecular weight marker. 
 
Western Blotting 
Following electrophoresis, the acrylamide gels were removed from their pre-cast 
casing and washed in Western Blot Transfer Buffer. The protein was transferred to 
Trans-Blot (Bio-Rad) nitrocellulose membrane by electroblotting using the XCell II 
Blot Module (Invitrogen). The membranes were then stained with Ponceau S. 
solution for five minutes. Excess stain was washed off with MQ water and the blot 
scanned to show effective transfer of protein. After washing the membranes for five 
minutes in TBS-T, the membranes were blocked in BSA solution (0.3% BSA, 1% 
PVP, and 1% PEG in TBS-T) for three hours at room-temperature to block non-
specific antibody binding. Primary antibody incubation used rabbit anti-Mighty 
antibody 1:5000 dilution in BSA solution at 4°C overnight, with gentle shaking. 
Following the incubation, the membranes were washed (five times five minutes) 
with TBS-T. The membranes were then incubated with goat anti-rabbit conjugated 
to horseradish peroxidase (HRP) (Amersham) 1:2000 dilution in BSA solution for 
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one hour. HRP activity was detected with ECL reagent (Western Lightning 
Chemiluminescense Reagent Plus). 
 
2.2.13 Statistical analyses 
Regeneration trial: 
ANOVA was carried out to confirm that the differences over time were due to the 
treatment not random variation. Student’s t-tests were carried out using the pooled 
standard deviation to determine significant differences in Mighty expression 
between wild-type and knock-out at each time point. Student’s t-tests were also 
carried out to determine significant changes in Mighty expression within each 
genotype compared to the uninjured control values. For MyoD expression Student’s 
t-tests were carried out to determine significant changes in expression levels within 
each genotype compared to the contra-lateral controls of the same time point. 
 
Satellite cell isolations: 
Student’s t-test was carried out to determine if there was a significant change in 
Mighty expression between wild-type and myostatin-null quiescent satellite cells, 
and between wild-type and myostatin-null activated satellite cells. A Mann-
Whitney test was also carried out on each data set. 
 
Reserve cell and myotube enrichments: 
Student’s t-test was used to determine significance differences in gene expression 
between myotubes and reserve cells of the same cell type. Student’s t-test was used 
to determine if there was a significant change in gene expression between control 
C2C12 cells and Mighty over-expressing clones of the same enrichment (e.g.: C2C12 
myotubes compared to Clone 7 myotubes). 
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Chapter Three 
Results 

3.1 Characterisation of isolated satellite cells 
To determine that the cells isolated by Percoll gradient (Section 2.2.1) were 
myogenic in origin, the isolated satellite cells were immediately fixed and then 
stained for MyoD. The immunocytochemistry showed that 92% of the cells 
were positive for MyoD. The negative control did not show any non-specific 
background staining; representative images are shown in Figure 3.1 A and E. 
The position of cell nuclei was determined by DAPI stain, as in Figure 3.1 B and 
F. 
 
To determine that the cells isolated by Matrigel adherence were myogenic in 
origin the protocol for isolation of activated satellite cells (Section 2.2.2) was 
followed. After the cells were allowed to attach and proliferate for a further 24 
hours in an 8-well chamber slide, they were fixed and stained for desmin. The 
immunocytochemistry showed that desmin was expressed by the majority of 
cells in the culture as seen in Figure 3.1 C. The position of cell nuclei was 
determined by DAPI stain, as in Figure 3.1 D. The percentage of myogenic cells 
has been determined several times in the laboratory, and is usually 80-85%. 




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Figure 3.1: Characterisation of isolated satellite cells. 
Cells isolated by Percoll gradient were fixed and stained for MyoD (A) and 
DAPI (B). Cells isolated by Matrigel adherence were fixed and stained for 
Desmin (C) and DAPI (D). Negative control (E) and DAPI (F) were carried out 
by omission of the primary antibody to ensure that non-specific antibody 
binding was not present. Microscope magnification: 400x. 
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3.2 Expression of Mighty in quiescent and activated satellite cells of wild-
type and myostatin-null mice. 
To determine if Mighty was present in quiescent and activated satellite cells 
from wild-type and myostatin-null mice, a 35 cycle PCR for Mighty was carried 
out. The results indicated that Mighty was present in both quiescent and 
activated satellite cells from both wild-type and myostatin-null mice. A semi-
quantitative analysis of the levels of Mighty was carried out by decreasing the 
cycle number of the PCR. Decreasing the cycle number to 28 showed that the 
quiescent satellite cells from wild-type and myostatin-null mice expressed less 
Mighty than activated satellite cells from wild-type and myostatin-null mice. No 
difference in Mighty expression in quiescent cells of wild-type and myostatin-
null mice was observed, as determined by Student’s t-test and Mann-Whitney 
tests, as shown in Figure 3.2 A. Decreasing the PCR cycle number to 22 cycles 
allowed the levels in activated satellite cells from wild-type and myostatin-null 
to be measured. No difference in the expression of Mighty in wild-type and 
myostatin-null activated satellite cells was observed, as determined by Student’s 
t-test and Mann-Whitney tests, as seen in Figure 3.2 B.  
 
Determination of Mighty levels in quiescent and activated satellite cells from 
wild-type mice was also carried out by Western Blot, as described in Section 
2.2.11. Levels of Mighty protein in wild-type quiescent satellite cells were 
undetectable and increased dramatically as satellite cells became activated, as 
shown in Figure 3.2 C. 
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Figure 3.2: Mighty RNA levels in quiescent and activated satellite cells 
A) Mighty levels in quiescent satellite cells from wild-type (Wt) and myostatin-
null (KO) mice. There was no significant expression difference between the two 
mouse types by Student’s t-test and Mann-Whitney test. B) Mighty levels in 
activated satellite cells from wild-type (Wt) and myostatin-null (KO) mice. 
There was no significant difference in Mighty expression between the two 
genotypes as determined by Student’s t-test and Mann-Whitney test. PCR was 
normalised to total RNA. Values represent the average of two PCRs. C) Mighty 
protein levels are up-regulated during activation in wild-type mice (normalised 
to total protein levels). 
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3.3 Effect of muscle injury on body and muscle weights 
The weight of the mice that had notexin-induced damage of the tibialis anterior 
(TA) muscle was taken twice. An initial weight was taken on the day of injury 
and a final weight was taken on the day of euthanasia. As shown in Figure 3.3, a 
decrease in weight during the first three days of the trial was observed in both 
wild-type and myostatin knock-out mice. The wild-type mice lost more weight 
than the myostatin-null mice. The myostatin-null mice appeared to regain any 
weight lost more rapidly than the wild-type mice. By day 28 post-injury the 
myostatin-null mice were significantly heavier (p=0.003) than the wild-type 
mice. 

The weight of both the damaged TA and the contra-lateral control muscles were 
taken at the time of excision. The weight of the notexin-damaged TA of the 
wild-type mice increased during the early stages of regeneration, becoming 
significantly heavier at day-three post-injury (p=0.03), as illustrated in Figure 
3.4 A. The weight of the notexin-damaged TA of the myostatin-null mice also 
increased during the first days of regeneration, and was significantly greater 
(p=0.04) at day-two post-injury, as seen in Figure 3.4, B. In both mouse models 
the weight of the damaged TA returned to normal by day-seven post-injury and 
mirrored the changes seen in the contra-lateral control until day-28 post-injury. 
The wild-type mice showed an increase in the damaged TA weight at day-28 
post-injury, a change that was not seen in the myostatin-null mice. 

Haematoxylin and eosin staining of control TA sections showed that both wild-
type (Figure 3.5 A) and myostatin-null (Figure 3.5 B) had healthy muscle with 
fibres surrounded by blue nuclei. Staining of tissue at day-one post-injury 
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revealed large areas of damaged tissue in both the wild-type (Figure 3.5 C) and 
myostatin-null (Figure 3.5 D) muscle. The extent of muscle damage is similar 
between both wild-type muscle and myostatin-null muscle, indicating that 
notexin was an efficient inducer of necrotic damage in the muscle regardless of 
the genetic background of the mouse. 
 
 
 


 
Figure 3.3: Body weight changes during muscle regeneration following 
notexin injection 
Over the initial days of regeneration both wild-type (light bars) and myostatin-
null mice (dark bars) lost body weight. By the end of the trial, the mice had 
regained this lost weight and had grown further. The myostatin-null mice grew 
to a greater extent than their wild-type counterparts. Values represent the mean 
of 5 animals ± SEM. Weight change is relative to the animal’s weight at day-
zero. **p<0.01 by Student’s t-test. 
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

 
Figure 3.4: Changes in weight of the tibialis anterior during regeneration 
following notexin injection 
A) Wild-type mice showed an increased weight of the injected TA by three days 
post-injury. The weight of the TA remained higher until day seven post-injury 
when it returned to be similar to the contra-lateral control. B) Myostatin-null 
mice showed an increased TA weight by day-two post-injury. As in wild-type 
mice, the weight of the myostatin-null TA returned to that of the contra-lateral 
control by day-seven post-injury. Each value represents the average of 5 animals 
± SEM. *p<0.05, **p<0.01 by Student’s t-test against the contra-lateral control 
at the same time point. 
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Figure 3.5: Notexin-induced damage of mouse tibialis anterior muscle 
Haemotoxylin and eosin staining of uninjured muscle from wild-type (A) and 
myostatin-null (B) mice showed healthy tissue. Staining of the TA tissue taken 
from wild-type (C) and myostatin-null (D) mice at day-one (D1) post-injury 
showed similar levels of damage had occurred in both mouse genotypes 
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3.4 Mighty was up-regulated during regeneration 
Control and notexin-injected muscles were either frozen in liquid nitrogen (n=3) 
for RNA analysis or in Tissue Tek O.C.T Compound (Sakura) (n=2) for 
immunocytochemistry of Mighty (Section 2.2.9.). RNA extraction and cDNA 
synthesis was carried out as described (Sections 2.2.5 and 2.2.6)

Short cycle PCRs for Mighty were carried out on wild-type TA cDNA template 
from an uninjured six week old wild-type mouse (Figure 3.6 A). Densitometric 
analysis showed that there was a linear increase in product density between 24 
and 28 cycles (Figure 3.6 B), hence a PCR cycle number of 26 was used to 
analyse Mighty levels in the regenerating muscle. 

As seen in Figure 3.6 C, the levels of Mighty in undamaged TA were 
significantly higher (p=0.001) in the myostatin-null mice than in the wild-type 
mice. Mighty cDNA levels in both mouse models stayed fairly constant over the 
days immediately after injury. Mighty levels peaked in both mouse types at day-
five post-injury. At day-five post-injury significantly more Mighty was present 
in the myostatin-null than in the wild-type samples (p=0.002). At day-seven 
after injury the Mighty cDNA levels in the myostatin-null mice were still 
elevated and are again significantly increased when compared to the wild-type 
levels (p=0.00001). At day-seven post-injury Mighty levels had dropped in the 
wild-type samples, although they remain higher than at day-zero (p=0.028). By 
day-14 the levels of Mighty in the myostatin-null mice have also decreased. 
Both mouse models showed an increase in Mighty at day-28 post-injury when 
compared to the day-zero values (p=0.001). 
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Figure 3.6: Mighty levels were increased during regeneration following 
notexin injection 
A) Ethidium bromide stained PCR products of cycle numbers 24, 26 and 28. 
B) PCR product increased linearly as cycle numbers were increased, indicating 
that the PCR was in the linear amplification stage. 
C) Mighty levels were increased in the injured TA of both wild-type and 
myostatin-null mice. Myostatin-null mice had a higher starting level of Mighty 
than wild-type mice and had an extended peak of Mighty expression between 
day-five and day-seven post-injury that was not seen in wild-type mice. Each 
value represents the average Mighty level of three animals ± SEM. #p<0.001 by 
Student’s t-test when compared to wild-type values. +p<0.05, *p<0.001 by 
Student’s t-test when compared to day-zero of the same genotype. 
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Immunocytochemistry for Mighty was carried on sections of tissue from 
damaged TA. Undamaged TA from myostatin-null mice had higher levels of 
Mighty than undamaged wild-type TA, determined visually, as seen in Figure 
3.7, A and B. At day-one post-injury there was no major change in the levels of 
Mighty in either wild-type (Figure 3.7 C) or myostatin-null (Figure 3.7 D) 
tissue. By day-five post-injury there had been an increase in Mighty in the wild-
type tissue (Figure 3.7 E) and in myostatin-null samples (Figure 3.7 F) there was 
an increase in the number of nuclei present within the muscle. At day-seven 
post-injury, wild-type muscle had a large increase in the number of nuclei 
present within the muscle and protein levels of Mighty appeared to remain high 
(Figure 3.8 A), though cDNA levels had decreased by this stage. The myostatin-
null tissue still showed high levels of Mighty at day-seven post-injury (Figure 
3.8 B). Tissues from day-14 post-injury (Figure 3.8 C and D) had reduced levels 
of Mighty. Wild-type tissue at this time had more nuclei present than the 
myostatin-null tissue. By day-28 post-injury the levels of Mighty protein had 
decreased in both the wild-type and the myostatin-null tissue, although levels 
remained higher than in the controls. Mighty levels in the myostatin-null tissue 
at day-28 post-injury (Figure 3.8 F) were higher than those seen in the wild-type 
tissue (Figure 3.8 E). 
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Figure 3.7: Mighty protein expression increased during early regeneration 
following notexin injection 
Uninjured muscle did not express high levels of Mighty. Myostatin-null (B) 
muscle showed higher levels of Mighty than wild-type (A). At day-one post-
injury (C and D) there was little change in Mighty levels. By day-five post-
injury myostatin-null muscle (F) showed greater numbers of infiltrating cells 
(indicated by an increase in blue nuclei, as determined visually) within the 
muscle than did the wild-type (E). By day-five post-injury both genotypes 
showed an increase in Mighty levels. Microscope magnification: 200x 
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Figure 3.8: Mighty protein expression during late regeneration following 
notexin injection 
At day-seven post injury both wild-type (A) and myostatin-null (B) tissue still 
had high levels of Mighty protein, determined visually. During the later stages 
of regeneration (day-14 and day-28 post injury) Mighty levels are still elevated 
in the myostatin-null mice (D and F) compared to the wild-type (C and E) at the 
same stage of regeneration. Microscope magnification: 200x 
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3.5MyoD levels were up-regulated during regeneration 
MyoD is one of the MRFs which is up-regulated shortly after satellite cell 
activation in injured muscle (Cooper et al., 1999) and is responsible for the 
induction of transcription of many myogenic genes. Mighty expression in 
relation to this gene was analysed to determine where Mighty might fit in the 
hierarchy of transcription factor expression during regeneration. 
 
Short cycle PCRs for MyoD (24, 26, and 28 cycles) were carried out on wild-
type TA cDNA template from an uninjured six-week-old mouse (Figure 3.9 A). 
Densitometric analysis showed that there was a linear increase in product 
density for MyoD between 24 and 28 cycles (Figure 3.9 B) and thus 26 cycles 
was chosen to use for MyoD analysis in the regenerating muscle. 
 
MyoD levels were up-regulated during early regeneration. In wild-type mice the 
levels began to increase at day-two post-injury and were significantly up-
regulated at day-five post-injury (p=0.02). By day-seven post-injury the MyoD 
levels in the damaged muscle had returned to those seen in the contra-lateral 
control muscle (Figure 3.10 A). In myostatin-null mice, the levels of MyoD in 
uninjured muscle are significantly higher than those in wild-type uninjured 
muscle (p=0.0004). MyoD levels in the damaged muscle did not increase over 
those in the contra-lateral control until day-three post-injury (p=0.03). The 
levels remain high at day five post-injury (p=0.03) before decreasing at day-
seven post-injury to the levels seen in the contra-lateral controls (Figure 310, 
B).


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Figure 3.9: MyoD PCRs were linear between 24 and 28 cycles 
Ethidium bromide staining of MyoD PCR products (A) between 24 and 28 
cycles indicates that the PCR was in the linear amplification stage as seen in (B). 
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Figure 3.10: MyoD levels were up-regulated during early regeneration 
following notexin injection 
A) In wild-type mice MyoD levels in the injured muscle began to be up-
regulated at day-two post-injury, although the levels were not significantly 
increased until day-five post-injury. MyoD levels returned to those of the 
contra-lateral control at day-seven post-injury. B) In myostatin-null mice MyoD 
levels were higher in undamaged muscle than in the wild-type. MyoD levels 
were elevated at three days post-injury in the damaged muscle and remain high 
at day-five. By day-seven post-injury the levels of MyoD had decreased to those 
in the contra-lateral control. Each value represents the average MyoD level of 3 
animals ± SEM. *p<0.05 by Student’s t-test when compared to contra-lateral 
control of the same time point and genotype. 
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3.6 Mighty localisation in reserve cell populations  
C2C12 and Mighty over-expressing clones (Clone 7 and Clone 11) were 
subjected to a limited trypsinisation as described in Section 2.2.4. Mighty ICCs 
were carried out on isolated reserve cell populations to determine how Mighty is 
localised in these cells. Negative controls, as seen in Figure 3.11 A were carried 
out by omitting the primary antibody to ensure that non-specific binding was not 
present. 
 
Mighty was localised primarily to the cytoplasm in the C2C12 reserve cells, as 
seen in Figure 3.11 B, although some cells did show some peri-nuclear staining. 
The Mighty over-expressing clones (Figure 3.11, C and D) both showed high 
levels of Mighty. Mighty was localised primarily to the peri-nuclear regions of 
these cells, although some cells, as indicated by asterisks, did show more 
cytoplasmic Mighty. 
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Figure 3.11: Mighty localisation in the reserve cell population 
A) Negative control. Microscope magnification for negative control: 200x 
Mighty localises mainly to the cytoplasm of C2C12 reserve cells (B) although 
some peri-nuclear staining is observed. In the Mighty over-expression clones 
(Clone 7 (C) and Clone 11 (D)), Mighty localised mainly to the peri-nuclear 
regions of the cells, although some cells only showed cytoplasmic staining 
(asterisks). Microscope magnification for B, C and D: 400x. 
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3.7 Downstream targets of Mighty 
Micro-array analysis of the gene expression of the Mighty clones in respect to 
the C2C12 cell line has been carried out to examine how Mighty influences gene 
expression. Several possible targets of Mighty have been identified. Two genes 
which are down-regulated are Sca-1 and CD34.  As both CD34 and Sca-1 
appear to play roles in myogenic differentiation (Epting et al., 2004; Mitchell et 
al., 2005), the down-regulation of their expression by Mighty was further 
investigated. 
 
3.7.1 Mighty decreased the levels of Sca-1 when over-expressed 
Short cycle PCRs for Sca-1 were carried out on mixed C2C12 cDNA template for 
20, 22, 24, 26 and 28 cycles (Figure 3.12 A). Densitometric analysis showed 
that there was a linear increase in product density between 22 and 28 cycles as 
seen in Figure 3.12 B. Initially a 22 cycle PCR was carried out on the reserve 
cell and myotube cDNA, however no product was able to be visualised (results 
not shown). Thus 26 cycles, which is still within the linear amplification stage of 
the PCR, was used to analyse the Sca-1 levels of the reserve cell and myotube 
populations. 

In normal C2C12 cells, the expression of Sca-1 was greater in the reserve cell 
population than in the myotube population. This pattern of expression was also 
seen in the Mighty over-expressing clones (Clone 7 and Clone 11). Overall the 
levels of Sca-1 in the reserve cell and myotube populations were decreased 
compared to the C2C12 control line, as seen in Figure 3.13 A (p= 0.02). Within 
the myotube population of the Mighty over-expressing clones, the levels of Sca-
1 decreased by 60-70% (p=0.002 for Clone 7 and 0.005 for Clone 11). In the 
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reserve cell population of the Mighty over-expressing clones, the levels of Sca-1 
decreased by 40-50% (p=0.01), as seen in Figure 3.13 B. 
 









 
Figure 3.12: Sca-1 PCRs were linear between 20 and 28 cycles 
Ethidium bromide staining of Sca-1 PCR products between 22 and 28 cycles (A) 
indicated that the PCR was in the linear amplification stage (B).
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Figure 3.13: Sca-1 levels were decreased by Mighty over-expression 
A) Levels of Sca-1 were greater in the C2C12 reserve cell population than in the 
myotube population. This pattern of expression was also seen in the Mighty 
over-expression clones, but the overall values are decreased compared to the 
C2C12 control. *p<0.05, **p<0.01 by Student’s t-test when compared to 
myotubes of the same cell type. B) Sca-1 was decreased by 60-70% in the 
myotube population and by 40-50% in the reserve cell population of the Mighty 
clones. *p<0.05, *p<0.01 by Student’s t-test when compared to C2C12 of the 
same cell population. Values represent the average of four PCRs ± SEM.  
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3.7.2 Mighty decreased the levels of CD34 when over-expressed 
Short cycle PCRs for CD34 were carried out on mixed C2C12 cDNA template 
for 22, 24, 26 and 28 cycles (Figure 3.14 B). Densitometric analysis showed that 
there was a linear increase in product density between 22 and 28 cycles. Figure 
3.14 B illustrates the linear change between 22 and 28 cycles. 24 cycles was 
used to analyse the reserve cell and myotube populations.  

The two forms of CD34, truncated and quiescent, are both detectable in the 
C2C12 myotube and reserve cell populations. The truncated form, which is 
expressed in quiescent satellite cells, was higher in the C2C12 reserve cells than 
in the myotubes. The truncated form of CD34 is also more highly expressed in 
the reserve cells of the two Mighty over-expression clones (Clone 7, p=0.008 
and Clone 11, p=0.02) but the overall levels were dramatically reduced from 
those seen in the C2C12 reserve cells, as shown in Figure 3.15 A and B. Over-
expression of Mighty caused a 95-98% decrease in truncated CD34 in the 
myotube population (Clone 7, p=0.0002 and Clone 11, p=0.0002) and a 80-90% 
decrease of truncated CD34 in the reserve cell population (Clone 7, p=7.8E-06 
and Clone 11, p=6.2E-05). 
 
The full-length transcript of CD34 is expressed in activated satellite cells. More 
full-length transcript was observed in the reserve cell population than in the 
myotube population of the C2C12 cells. The same expression pattern was 
observed in Clone 7 (p=0.003) and Clone 11 (p=0.004) As with the truncated 
form, the overall levels of the full-length transcript were dramatically reduced in 
the Clone 7 and Clone 11 samples when compared to the C2C12 controls (Figure 
3.16 A). Mighty caused a 90-95% decrease of the full form of CD34 in the 
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myotube population (Clone 7, p=1.2E-05 and Clone 11, p=1.2E-05) and a 70-
85% decrease in the reserve cell population (Clone 7, p=0.0001 and Clone 11, 
p=0.0008) of the Mighty over-expression clones (Figure 3.16 B). 
 
 
 

 
 
 
 
 
 
 
 
Figure 3.14: CD34 PCRs were linear between 22 and 28 cycles. 
A) Ethidium bromide stained CD34 PCR products. B) CD34-truncated PCR 
product increased linearly as cycle numbers were increased, indicating that the 
PCR was in the linear amplification stage. C) CD34-full PCR product increased 
linearly as cycle numbers were increased, indicating that the PCR was in the 
linear amplification stage. 
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Figure 3.15: The truncated form of CD34 as decreased when Mighty was 
over-expressed. 
A) C2C12 reserve cell enrichment showed higher expression of the truncated 
form of CD34 than the myotube enrichment. This pattern was preserved in the 
Mighty over-expressing clones, but the overall values were decreased compared 
to the C2C12 control. *p<0.05, **p<0.01 by Student’s t-test when compared to 
myotubes of the same cell type. B) The percent decrease of the truncated form 
of CD34 was 95-98% in the myotube enrichments and 80-90% in the reserve 
cell enrichments of the Mighty clones. **p<0.01 by Student’s t-test when 
compared to C2C12 of the same cell population. Values represent the average of 
four PCRs ± SEM. 
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Figure 3.16: The full-length form of CD34 was decreased when Mighty was 
over-expressed. 
A) C2C12 reserve cell enrichment showed higher expression of the full form of 
CD34 than the myotube enrichment. This pattern was preserved in the Mighty 
over-expressing clones, but the overall values were decreased compared to the 
C2C12 control. **p<0.01 by Student’s t-test when compared to myotubes of the 
same cell type. B) The percent decrease of the full form of CD34 was 90-95% in 
the myotube enrichment and 70-85% in the reserve cell enrichments of the 
Mighty over-expression clones. **p<0.01 by Student’s t-test when compared to 
C2C12 of the same cell population. Values represent the average of four PCRs ± 
SEM. 
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Chapter Four 
Discussion and Future Directions 
 
4.1 Discussion 
Satellite cells are the major myogenic precursors that contribute to post natal 
muscle growth and repair and were first identified by Katz (1961). Satellite cells 
activate, proliferate and differentiate into new muscle fibres in response to 
signals from their environment. Satellite cells are also capable of self-renewal to 
replenish the satellite cell niche and provide nuclei for future growth/repair 
needs. The myostatin-null mouse model has been shown to contain more 
satellite cells per fibre than wild-type mice. These satellite cells also have a 
greater propensity to activation and proliferation than cells isolated from wild-
type mice (McCroskery et al., 2003). After muscle injury, myostatin-null mice 
have twice the number of myogenic cells, identified by MyoD, at the site of 
injury than wild-type mice. Healing is more complete, with less fibrosis and scar 
tissue formation when myostatin is absent (McCroskery et al., 2005). This 
evidence implicates myostatin as a negative regulator of satellite cells. One 
downstream target of myostatin, the novel gene called Mighty, is up-regulated in 
myostatin-null mice. Mighty over-expression results in enhanced differentiation 
and fusion of C2C12 cells and a hypertrophy phenotype. The expression of 
Mighty during satellite cell activation and regeneration of skeletal muscle was 
investigated in this thesis. 
 
To first participate in muscle growth or regeneration, satellite cells must leave 
quiescence and activate. This activation in response to growth factors such as 
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IGF’s (Hill and Goldspink, 2003) is an essential step in the regeneration and 
growth program. Myostatin-null mice, which express higher levels of Mighty 
than wild-type mice, have a greater number of satellite cells that have a greater 
propensity to activation (McCroskery et al., 2003). We hypothesised that 
Mighty acts as a regulatory factor during this process and thus expected that 
activated satellite cells from myostatin-null mice would have more Mighty than 
those from wild-type mice. As shown in Figure 3.2 A, Mighty was expressed at 
a low level in quiescent satellite cells of both wild-type and myostatin-null mice. 
As expected, activated satellite cells had more Mighty cDNA than quiescent 
cells. However, the levels of Mighty between wild-type and myostatin-null mice 
were not significantly different by Mann-Whitney and Student’s t-test. If Mighty 
is involved in the activation of satellite cells it is likely that peak levels occur 
during the first activation events. The satellite cells used in this experiment had 
already been cultured for 48 hours and it is possible that the peak of Mighty 
expression has been missed. Single fibre cultures would be a more accurate way 
of determining when the peak of Mighty expression occurs in relation to 
markers of satellite cell activation in both wild-type and myostatin-null satellite 
cells. 
 
After activation, the regeneration of skeletal muscle requires migration of 
activated satellite cells to the site of injury, their proliferation, and then their 
commitment to terminal differentiation. Once committed, satellite cells will then 
fuse to other myoblasts or to existing fibres (Hawke and Garry, 2001). 
Myostatin-null mice show an improved regeneration phenotype, with less 
fibrosis and scar tissue formation (McCroskery et al., 2005). Mighty is 
hypothesised to enhance satellite cell commitment to the myogenic 
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differentiation programme, which results in the enhanced regeneration 
phenotype. To characterise Mighty expression during regeneration, wild-type 
and myostatin-null mice were used for notexin injection. On days 0, 1, 2, 3, 5, 7, 
14 and 28 five mice from each genetic background were euthanised. Notexin is 
a cardiotoxin that is commonly used to induce muscle damage and regeneration. 
Notexin injection to the TA results in localised muscle damage and overall 
faster healing than crush injury (Lefaucheur and Sebille, 1995). Histologically, 
notexin injection causes consistent patterns of muscle injury over time and 
between rats that have different genetic backgrounds (Kirk et al., 1996: Kirk et 
al., 2000). Figure 3.5 shows that notexin induced comparable levels of damage 
in both mouse genotypes used in this study. 
 
To determine the expression of Mighty during regeneration, a series of PCRs on 
undamaged wild-type mouse cDNA was carried out. The purpose of this was to 
determine the cycle numbers at which the PCR was in the linear phase of 
amplification. By analysing PCRs in the linear phase, the differences between 
samples can be semi-quantitatively determined. Levels of Mighty were 
significantly higher in the myostatin-null mice at day-zero (uninjured muscle) 
than in the wild-type mice. This difference was as expected and conforms to the 
differences seen in other experiments carried out. Mighty up-regulation at the 
messenger RNA level was not seen until day-five post-injury. Both wild-type 
and myostatin-null mice have significantly up-regulated Mighty cDNA at day-
five compared to the undamaged day-zero levels. Most importantly, Mighty 
remained significantly up-regulated in myostatin-null mice at day seven post-
injury compared to the wild-type mice. 
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Immunocytochemistry on sections of damaged tissue also revealed differences 
in the regeneration response of the two mouse genotypes. As seen in Figure 3.7, 
undamaged myostatin-null TA showed higher levels of Mighty protein 
expression, consistent with the cDNA data. By day-five post-injury the 
myostatin-null mice showed a large increase in the number of infiltrating nuclei 
present within the tissue, as well as an increase in the levels of Mighty protein. 
At day-seven post-injury Mighty protein levels within the wild-type tissue 
remained elevated, despite the decrease in cDNA levels described earlier. 
Mighty protein was persistent in the muscle longer than the transcript was. It is 
possible that Mighty protein levels in the myostatin-null background also persist 
beyond the down-regulation of transcription, but time points that would allow 
this to be determined were not taken. By day-14 post-injury Mighty protein 
levels in both mouse models had decreased, and at day-28 they were decreased 
further, although they had not yet decreased back to the levels seen in the 
undamaged controls. 
 
MyoD is one of the four myogenic regulatory factors (MRFs) that are essential 
for myogenensis in the embryo. MyoD or Myf-5 are undetectable in the majority 
of quiescent satellite cells (Grounds et al., 1992). As these cells become 
activated in response to injury, they will express either MyoD or Myf-5 (Cooper 
et al., 1999). By 48-hours post-injury, activated satellite cells co-express MyoD 
and Myf-5 and most go on to express Myogenin and MRF4 (Cornelison and 
Wold, 1997). During the regeneration time-course studied here, MyoD levels in 
wild-type mice started to increase at day two post-injury but were not 
significantly increased until day-five post-injury. In the myostatin-null mice, a 
similar pattern of MyoD expression was observed. MyoD did not increase over 
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the contra-lateral control values until day-three post-injury but the increase is 
significant at this stage. MyoD remains elevated until day seven post-injury, at 
which stage the levels decreased to those of the contra-lateral control. 
 
The results displayed for the change in Mighty and MyoD message levels 
throughout regeneration are indicative of trend. During the regeneration process 
we found that two commonly used housekeeping genes, tubulin (McCroskery et 
al., 2003) and HPRT (hydroxanthine guanine phosphoribosyl transferase) (Rios 
et al., 2002) were both up-regulated (data not shown). GAPDH expression is 
also altered during regeneration (McCroskery et al., 2005). Several studies have 
shown that these commonly used genes are variably expressed in different 
tissues and proliferation or differentiation states. GAPDH and -actin levels 
fluctuate during keratinocyte differentiation (Steele et al., 2002) and during 
arteriogenesis in the rabbit (Deindl et al., 2002), HPRT and -tubulin levels vary 
in differentiating embryonic stem cell culture (Murphy and Polak, 2002), 
GAPDH expression is altered during T helper cell differentiation (Hamalainen 
et al., 2001) and in breast cancers when compared to control tissue (Tricarico et 
al., 2002). There is little consensus as to which gene should be examined as a 
housekeeper during muscle regeneration (McKinnell et al., 2005). When 
considering the extensive nature of the notexin-induced damage to the muscle, 
as shown in Figure 3.5, it is hardly surprising that genes which under normal 
conditions act as housekeeping genes are not suitable as internal controls. 
Structural proteins such as tubulin are required during muscle rebuilding and the 
increased cellular activity required to regenerate the muscle would require an 
increase in the molecules involved with energy generation, such as GAPDH 
(Vascotto et al., 2005), and the metabolic salvage of nucleotides, such as HPRT 
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(de Kok et al., 2005). To partially alleviate this problem, all cDNA synthesis 
reactions were carried out on equal amounts of total RNA as determined by 
spectroscopy using a Nanodrop ND-1000 spectrophotometer (NanoDrop 
Technologies). 
 
Analysis of the pattern of expression of the MRFs during regeneration revealed 
that MyoD is slowly up-regulated in the days following injury to a peak at day-
three post-injury. Myogenin also peaks at day-three post-injury, with Myf-5 and 
MRF4 expression being maximal at day-five post-injury (Yan et al., 2003). 
Cornelison and Wold (1997) showed that by 48 hours post-injury activated 
satellite cells express both MyoD and Myf-5. Kirk et al. (2000) described two 
phases of regeneration, the damage phase which occurs in the first three days 
following injury, in which expression of myostatin peaks; and a regeneration 
phase from day-five post-injury. Day five post-injury was described as the time 
at which peak myotube formation was occurring. In vitro myostatin negatively 
regulates proliferation of myoblasts (Thomas et al., 2000) and its expression 
during the early phases of regeneration is consistent with a role in maintaining 
satellite cells in a non-proliferative state while necrotic tissue is removed by 
phagocytosis.  Myostatin has been shown to negatively regulate the Mighty 
promoter (Bishop, 2005), and in the myostatin-null mice, the lack of myostatin 
resulted in an increase of Mighty expression in undamaged muscle compared to 
the wild-type mice. Mighty up-regulation in both wild-type and myostatin-null 
tissue during regeneration did not occur until day-five post-injury, the time 
when myotube formation is occurring. Events at this time involve fusion of 
myoblasts to each other and to existing myotubes, and Mighty up-regulation at 
this time point is consistent with a role for Mighty in inducing hypertrophy of 
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muscle via enhanced myoblast fusion and of myostatin negatively regulating 
Mighty. Interestingly, Mighty up-regulation occurs at the same time in both 
wild-type and myostatin-null tissues. This indicates that myostatin is involved 
with maintaining a basal level of Mighty expression in normal muscle tissue, 
and that the up-regulation seen at day-five post-injury is in response to other 
factors. MyoD is one factor that is capable of increasing transcriptional activity 
of the Mighty promoter, although this increase is slight (2-fold; Bishop, 2005). 
Other transcription factors that have binding sites within the Mighty promoter, 
such as Sp1, may be responsible for the increase in Mighty expression seen at 
day-five post-injury. Mighty has also been shown to specifically up-regulate 
mediators of cell cycle withdrawal, such as p21 and p27 (Bishop, 2005), thus 
expression of Mighty at the time of myotube formation is consistent with 
Mighty playing a role in enhancing differentiation. Myostatin expression is seen 
in regenerating myotubes from day-five post-injury (Kirk et al., 2000) and this 
increase is likely to result in the down-regulation of the Mighty transcript in the 
wild-type tissue. Further results from the FMG Laboratory indicate that Mighty 
is down-regulated as commitment to terminal differentiation occurs, thus the 
decrease in Mighty expression seen in both the wild-type and myostatin-null 
genotypes could be due to terminal differentiation of the satellite cells. 
 
When C2C12 cells are induced to differentiate, a proportion of the cells commit 
to terminal differentiation, while a different population withdraw from the cell 
cycle and do not differentiate. Isolation and culture of undifferentiated cells 
results again in the formation of two populations of cells; one differentiated, one 
undifferentiated (Yoshida et al., 1998). This reserve cell population is akin to 
the satellite cell population seen in vivo. As such it can act as an in vitro model 
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for the events occurring in vivo. Mighty, which is, as has been stated previously, 
a downstream target of myostatin, causes an enhanced fusion phenotype when 
over-expressed. Cultures of differentiated Mighty over-expression clones have 
larger myotubes and fewer reserve cells than are seen in normal C2C12 culture. 
This observation has lead to the hypothesis that Mighty is involved in 
hypertrophy by enabling the recruitment of more reserve cells into the 
differentiation pathway. Two possible down-stream targets of Mighty, stem cell 
antigen-1 (Sca-1) and CD34, may be involved in this process. 
 
Sca-1 was identified by micro-array analysis as being down-regulated in the 
Mighty over-expression clones. To further characterise this decrease, Sca-1 
primers as described in Mitchell et al. (2005) were standardised on cDNA from 
C2C12 cells.  Analysis of the myotube and reserve cell populations revealed that 
in C2C12 cells the level of Sca-1 was significantly higher in the reserve cell 
population than in the myotube population. This same pattern of expression was 
preserved in the Mighty over-expression clones. However the absolute levels 
were decreased from those seen in the C2C12 populations, as was expected based 
on the micro-array data. Levels of Sca-1 decreased by 60-70% in the myotube 
population and by 40-50% in the reserve cell population. Epting et al. (2004) 
and Mitchell et al. (2005) proposed that expression of Sca-1 acts to keep a 
population of myoblasts in a slowly proliferating non-dividing state that is 
capable of giving rise to reserve cells. Sca-1 decrease by Mighty may result in a 
larger proliferative and differentiation competent myoblast population during 
growth and differentiation. This could result in myotube hypertrophy and in a 
smaller reserve cell population that is a characteristic of Mighty over-
expression. 
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CD34 was also identified by micro-array analysis as being down-regulated by 
Mighty over-expression. To analyse this further, PCR primers as described by 
Beauchamp et al. (2000) were used. These particular primers give two PCR 
products, depending on the form of CD34 that is present. This allowed analysis 
of both truncated CD34 and full-length CD34 levels from the same PCR. Both 
the truncated form of CD34, which is expressed on quiescent satellite cells 
(Beauchamp et al., 2000), and the full-length form of the CD34 transcript were 
present in the reserve cell and myotube populations. Levels of both CD34 
transcripts were significantly down-regulated in both the myotube and reserve 
cell populations by Mighty over-expression. These results for both CD34 full 
and CD34 truncated were as expected from the micro-array analysis. 
 
CD34 may function in muscle to keep a subpopulation of proliferative cells 
from differentiating. This theory is substantiated by the recent results of 
Kitzmann et al. (2006), who showed that the reserve cell population was 
heterogeneous for CD34 expression and that inhibition of notch was specifically 
able to increase the fusion of CD34-negative cells. Notch inhibition by its 
antagonist numb causes proliferating myoblasts to commit to terminal 
differentiation (Conboy and Rando, 2002). The inhibition of notch by over-
expressing numb or by use of a -secretase inhibitor resulted in an enhanced 
fusion index of the myoblasts and increased differentiation (Kitzmann et al., 
2006). Consistent with this, our results indicate that down-regulation of CD34 
by Mighty could result in a population of cells that are more sensitive to fusion 
and differentiation signals and more sensitive to signalling through the notch 
pathway.  
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4.2 Future Directions 
4.2.1 Mighty and regeneration. 
The results described in this thesis indicate that there is a large up-regulation of 
Mighty during the regeneration process. This up-regulation occurs after the 
induction of MyoD. Further characterisation of the major myogenic regulatory 
factors during regeneration needs to be carried out, so that Mighty’s place in the 
hierarchy of regulatory factors can be determined. Once the timing of Mighty 
expression in relation to these other factors is known, the factors that are 
expressed before Mighty can be analysed to determine if they are capable of 
directly influencing the regulation of the Mighty promoter. It is already known 
that MyoD is capable of causing an increase in transcriptional activity of the 
Mighty promoter. Testing of the other transcription factors that have binding 
sites within the Mighty promoter to determine their ability to up-regulate or 
down-regulate Mighty during myogenensis and regeneration needs to be carried 
out. Furthermore, Mighty may be able to auto-regulate its own transcription, 
which is a possibility that also needs to be determined. Finally, the effect of 
positive regulators of satellite cell activation and proliferation such as HGF and 
IGF on Mighty transcription needs to be determined. 
 
4.2.2 Mighty and Reserve Cells 
Mighty has been shown in previous experiments to cause an increase in 
hypertrophy and myoblast fusion when over-expressed. This results in a smaller 
reserve cell population after complete differentiation than is seen in control 
C2C12 cultures. Over-expression of Mighty also causes a decrease in two 
molecules that are considered markers of less differentiated, stem cell-like cells, 
CD34 and Sca-1. Firstly, the mechanism by which Mighty is able to negatively 
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regulate the promoters of these genes need to be determined. Secondly, the role 
of these molecules in causing the enhanced fusion phenotype needs to be 
resolved. Some possibilities have come to light from recent papers. If Sca-1 acts 
as a determining factor that allows cells to take the self-renewal pathway during 
differentiation, then a direct down-regulation of this factor may cause the 
phenotype seen in the Mighty over-expressers. CD34 has recently been shown 
to influence the sensitivity of cells to Notch signalling (Mitchell et al., 2005). It 
would be of interest to determine if the Notch signalling pathway is altered in 
the Mighty over-expression clones. 
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Appendix 
Agarose 
0.5 g UltraPure agarose (Invitrogen) 
50 ml 1 x TAE buffer 
Boiled until agarose is dissolved.  
1 µl 10 mg/ml ethidium bromide per 50 ml Agarose. 
  
Assay Buffer (2 x) for -gal detection assay 
2 ml 200 mM sodium phosphate buffer 
20 µl 2 mM magnesium chloride 
71.4 µl 100 mM -mercaptoethanol 
3.33 ml 1.33 µg/µl ONPG 
MilliQ water to 10 ml 
  
Collagenase (0.2%) 
30 ml DMEM (no serum) 
0.06 g Collagenase Type 1A (Sigma) 
Dissolved then syringe filtered through a Millex GP 0.22 m filter (Millipore) 
 
Denaturing RNA agarose gel 
0.6 g agarose 
36 ml DEPC treated water 
Boil to dissolve agarose then cooled to ~60oC 
In fume hood add: 
5 ml 10 x MOPS 
9 ml formaldehyde 
  
DEPC (diethyl pyrocarbonate)-treated water 
2 ml DEPC 
2 l MilliQ water 
Mixed overnight then autoclaved. 
 
Differentiation medium 
Dulbecco's modified Eagle medium (DMEM) 
2% horse serum 
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DNA 1kb+ Ladder 
90 µl 10 x DNA loading dye 
810 µl MilliQ water 
100 µl 1 µg/ml 1kb+ ladder 
  
DNA Loading Dye (10 x) 
10 ml 50% glycerol 
2 ml 50 x TAE 
Pinch of bromophenol blue 
 
Eosin (1% solution) 
10 g Eosin Y 
1 l MilliQ water 
2.0 ml acetic acid (5% aqueous) 
1 crystal of thymol 
 
Gill’s Haematoxylin 
4.0 g Haematoxylin 
0.4 g sodium iodate 
35.2 g aluminium sulphate 
710 ml MilliQ water 
250 ml ethylene glycol 
40 ml glacial acetic acid 
 
Matrigel 
200 l Matrigel 
1800 l DMEM 
Bottom of plate is covered, excess is removed. Plate kept at 37oC to allow 
Matrigel to set. 
  
MOPS (10 x) Solution (3-[N-Morpholino]propane-sulfonic acid) 
41.8% MOPS powder 
50 mM sodium acetate 
10 mM EDTA 
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PBS (Phosphate Buffered Saline) 
1 PBS tablet (Oxoid) 
100 ml MilliQ water 
  
PBS (10x) 
1 PBS tablet 
10 ml MilliQ water 
  
Percoll (90%) 
9 parts Percoll solution 
1 part 10 x PBS 
  
Percoll (70%) 
2.33 ml 90% Percoll 
0.67 ml 1 x PBS 
  
Percoll (40%) 
1.33 ml 90% Percoll 
1.67 ml 1 x PBS 
 
Ponceau S stain 
0.1% Ponceau S 
0.1% Acetic acid 
Make up to desired volume with MilliQ water 
  
Protein loading buffer 
3 parts 4 x NuPage sample buffer 
1 part -mercaptoethanol 
 
Protein lysis buffer 
50 mM Tris (pH 7.5) 
250 mM sodium chloride 
5 mM EDTA 
0.1% NP-40 
1 x Protease inhibitor 
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RNA Loading Dye (2 x) 
2 ml MOPS (10 x) 
2 ml deionised formaldehyde 
5 ml deionised formamide 
40 µl of 10% bromophenol blue 
1 ml glycerol 
100 µl of 0.5 M EDTA (pH 8.0) 
40 µl of 10 mg/ml ethidium bromide 
  
RNA running buffer 
1 part 10 x MOPS 
9 parts DEPC water 
  
Satellite cell proliferation media 
50 ml DMEM (2x) 
8 ml bicarbonate solution 
1 ml penicillin/streptomycin 
20 ml FBS 
10 ml HS 
1 ml chicken embryo extract 
Make up to 100 ml with MilliQ water 
 
Scott’s tap-water 
2.0 g sodium bicarbonate 
20.0 g magnesium sulphate 
1 l MilliQ water 
1 crystal of thymol 
 
 TAE (Tris-acetate EDTA) for DNA gels (50 x) 
242 g Tris (base) 
57.1 ml glacial acetic acid 
100 ml 0.5 M EDTA (ph 8.0) 
Made up to 1 l with MilliQ water 
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TBS (Tris buffered saline) 
50 ml 1 M Tris 
30 ml 5 M Sodium chloride 
Made up to 1 l with MilliQ water 
  
TBS-T (Tris buffered saline + Tween-20) 
999 ml TBS 
1 ml Tween-20 
 
Western blocking buffer 
0.15 g BSA 
0.5 g PVP 
0.5 g PEG 
50 ml TBS-T 
 
Western transfer buffer 
25 mM Tris 
190 mM glycine 
20% methanol 
  
20:2:1 fixative 
20 parts 70% ethanol 
2 parts 40% formaldehyde 
1 part glacial acetic acid 
 
75% ethanol 
75 ml 100% ethanol 
25 ml DEPC-treated water 
 
0.35% Carageenen-lambda 
0.175 g Carageenen from seaweed (Sigma) 
50 ml PBS 
 
10% serum 
20 l serum 
1980 l PBS 
 
  88 
0.5% Triton X-100 
250 l Triton X-100 
49.75 ml PBS 
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